Neither is useful.

That’s why I created the Probiotic Decision Kit.

It’s an 80+ page, science grounded guide designed to help wellness professionals, dietitians, naturopaths, clinicians, and informed consumers think more critically about probiotics.

The kit walks through how to evaluate:

• strain specificity

• clinical evidence

• product quality

• dose and formulation

• intended use

• client or patient context

• common marketing claims

• when the evidence is strong, weak, or simply not there

It also includes practical worksheets and decision tools so you can move from “this probiotic sounds good” to a much more structured question:

Does this specific product make sense for this specific person and this specific goal?

One thing the kit does not try to do is turn diet into a few bullet points.

Food choices, dietary pattern, fiber, fermentation, and the way diet shapes the gut ecosystem are huge topics in their own right. They deserve a much deeper treatment than a sidebar in a probiotic guide. That’s something I plan to explore separately.

The goal of this kit is narrower and, I think, more useful: to give you a framework for making better probiotic decisions without getting lost in marketing language or microbiome hype.

If you work with clients or patients and find yourself wishing you had a more rigorous way to talk about probiotics, this was built for you.

The Probiotic Decision Kit is available here:
https://wdepaolo.gumroad.com/l/probiotic-decision-kit

You can currently get 20% off with code FNF 2026.

And if you’ve already purchased it, I’d genuinely love to hear what you’ve found most useful and what you’d like to see me build next.

Subscribe now

A client sits down, pulls a probiotic bottle from a bag, and asks the question every nutrition professional knows. Which one should I take? The label is crowded with billions, proprietary blends, bold promises, and scientific looking names. The pressure is immediate because the client expects a product answer. Yet the most important work comes before product selection. The useful question is what outcome the client wants to change and how anyone will know whether the product helped.

The probiotic market has trained consumers to treat quantity as quality. A larger CFU number feels stronger, more advanced, and more likely to work. CFU gives a count of viable organisms under defined conditions. It cannot tell us whether the organisms match the client goal, whether the strain has relevant human evidence, whether potency lasts through expiration, or whether the product belongs in the conversation at all. The impressive number on the front of the bottle can therefore become the least useful number in the decision.

The bottle has already won

When the conversation begins with a brand, the bottle quietly sets the agenda. The client goal gets squeezed into whatever the product claims to support. Bloating becomes balance, fatigue becomes vitality, and a complicated symptom history becomes general gut health. This reversal invites overpromising because the person is asked to fit the product. Better practice starts with the person, the desired outcome, the relevant health context, and the evidence required for that specific use.

This principle aligns with major professional guidance. The World Gastroenterology Organisation connects probiotic benefits to specific strains or strain combinations at an effective dose. The National Institutes of Health also emphasizes that clinical recommendations need to account for strain identity and that many commercial products have never been examined directly. Those details make generic rankings especially weak. A recommendation becomes defensible when the organism, dose, formulation, population, and outcome line up well enough to justify a careful plan.

World Gastroenterology Organisation guidance • National Institutes of Health professional fact sheet

A probiotic recommendation needs an exit plan

Even a reasonable probiotic trial can drift into permanent use through inertia. The client keeps buying it because stopping feels risky, while the professional never defined success or a reassessment date. Cost accumulates and attribution becomes impossible once several supplements or diet changes begin together. A trial deserves one product, one clear rationale, one or two trackable outcomes, and a point when the result will be reviewed. It also deserves a stop rule for worsening symptoms, poor value, absent benefit, or a need for medical evaluation.

That is the logic behind Try, Track, Stop, one of the core tools in my Probiotic Decision Kit. Try means choosing one product with a clear reason and an agreed trial period. Track means selecting outcomes a client can realistically monitor, such as stool pattern, urgency, bloating severity, or impact on daily life. Stop means deciding in advance when the trial ends and what would trigger earlier reassessment. The framework turns a supplement purchase into a transparent experiment with an endpoint.

Sometimes the best probiotic decision is referral

A strong decision framework earns its value when it prevents the wrong next step. A client asking about bloating may also report unintentional weight loss, blood in the stool, or a meaningful change in bowel habits. Those details should redirect the conversation toward clinical evaluation. Product comparison can wait while the client receives appropriate care. The professional has still answered the probiotic question, because sound judgment includes knowing when the supplement aisle should leave the frame.

This is where probiotic education becomes professional infrastructure. Practitioners need language that preserves trust while explaining uncertain evidence, vague labels, unrealistic claims, and reasons to pause. They also need a repeatable intake process, documentation, product evaluation criteria, and client materials that make the reasoning visible. Confidence comes from a method that can be explained and repeated. It does not come from memorizing a rotating list of popular brands.

Why I built the Probiotic Decision Kit

I created the Probiotic Decision Kit for dietitians, nutrition professionals, wellness coaches, naturopathic and integrative practices, clinical teams, and scientifically engaged consumers who want a more rigorous process. The final 88 page toolkit includes a five question framework, a decision tree, label guidance, common client scripts, safety and referral considerations, case studies, printable client handouts, intake tools, a product evaluation worksheet, and a strain evidence reference. It begins with the client goal and carries the decision through context, evidence, label review, trial design, reassessment, and referral when appropriate. Every section is designed to support an actual conversation rather than decorate a shelf. The kit gives professionals a way to be useful without pretending that every probiotic question has a quick product answer.

The probiotic field keeps producing more strains, more formulas, more claims, and more confusion. Another ranked list will age quickly and teach very little. A durable framework improves each future decision because it teaches the practitioner what to ask, what to inspect, what to document, and when to stop. Better probiotic advice begins when the bottle loses control of the conversation. Better questions put the client and the evidence back in charge.

Bring a decision process into your next probiotic conversation

The Probiotic Decision Kit gives you 88 pages of practical guidance, scripts, worksheets, handouts, and evidence tools. Use it to define the client goal, evaluate a product, plan a structured trial, and recognize when referral belongs first. The kit is available as an immediate digital download. Open it before the next bottle lands on your desk.

Get the Probiotic Decision Kit

The Medicines and Healthcare products Regulatory Agency has published a new position paper explaining how microbiome based medicinal products can be developed and authorized in the UK.

That sounds procedural. It is actually a meaningful regulatory signal.

The microbiome field has spent years talking about transformative therapies while struggling to answer a basic question. What exactly is the product?

Is it one bacterial strain? A defined community? A donor derived ecosystem? A collection of spores? A nonliving microbial preparation? A metabolite? A therapy that changes the microbiome, or a therapy produced by microorganisms?

The MHRA has now provided a broad answer.

A microbiome based medicinal product may contain live organisms, defined consortia, complex microbial ecosystems, nonviable organisms, or components derived from microorganisms. Its principal therapeutic effect must operate through the modulation, restoration, replacement, or functional activity of the human microbiome.

That definition is broad enough to cover much of the field now emerging.

The paper also makes clear that these products can be licensed through the existing UK medicines framework. Developers will need to demonstrate quality, safety, and efficacy, just as they would for other medicines.

This is good news.

It is also only the beginning.

The MHRA has opened the regulatory door. It has yet to give developers a sufficiently detailed path through it.

Why the UK position matters

Regulatory uncertainty can quietly kill a therapeutic field.

Companies hesitate to invest when they cannot determine how a product will be classified, what evidence will be required, or whether the regulator has a viable route to approval. Manufacturing programs stall. Clinical trials are designed around uncertain assumptions. Investors wait for another company to take the first risk.

The MHRA has now stated that microbiome based medicines are acceptable in principle and capable of meeting UK standards for marketing authorization. It tells developers that the regulatory system can accommodate these products. It also tells patients and clinicians that microbiome therapeutics should eventually be held to the standards expected of medicines.

The paper gets several important scientific issues right.

It recognizes that a microbial medicine may change during manufacturing, storage, and administration. It emphasizes product characterization, critical quality attributes, potency, batch consistency, and stability.

It also recognizes that biological variability cannot become a permanent excuse for weak product control.

A complex microbial product may be inherently variable. That variability still has to be measured, bounded, and connected to safety and therapeutic function.

The MHRA also addresses contamination, infection in vulnerable patients, horizontal gene transfer, and antimicrobial resistance. These are central safety questions for any product capable of carrying living organisms or transferable genetic material into a patient.

Perhaps most encouragingly, the agency acknowledges that conventional animal models may provide limited information about products designed to interact with the human microbiome. It supports scientifically justified alternative methods and integrated evidence when animal studies have poor predictive value.

That is a realistic position. A mouse microbiome is not simply a smaller human microbiome. Species differences can change colonization, metabolism, immune responses, ecological interactions, and treatment effects.

The new position therefore gives the field something valuable.

Regulatory permission.

The United States already has something the UK lacks

The United States has no single umbrella category equivalent to the new UK definition. Its framework is narrower and more fragmented.

Live biotherapeutic products, fecal microbiota products, engineered microorganisms, microbial components, and other microbiome directed interventions may follow different regulatory routes depending on their composition and intended use.

Yet the United States has one major advantage.

It has already approved products.

The Food and Drug Administration approved Rebyota in November 2022 and Vowst in April 2023. Both are donor derived fecal microbiota products intended to prevent recurrent Clostridioides difficile infection in adults following antibiotic treatment.

Rebyota is administered rectally. Vowst is administered orally.

These approvals are narrow. They do not validate microbiome therapeutics across cancer, metabolic disease, inflammatory disease, or neurological conditions. They demonstrate that a complex microbial product can be characterized, manufactured, clinically tested, reviewed, and licensed as a biological product.

That precedent is enormously valuable.

American developers can examine actual approval letters, clinical reviews, manufacturing assessments, benefit and risk evaluations, and product specifications. The FDA has also maintained specific manufacturing guidance for early clinical trials with live biotherapeutic products.

The FDA guidance addresses issues such as strain identity, microbial purity, antibiotic resistance, adventitious agents, manufacturing processes, stability, and product testing.

The United States therefore has a narrower framework with more operational history.

The UK has produced a broader framework with greater conceptual flexibility.

The difference can be stated simply.

The FDA can point to products that crossed the finish line. The MHRA can currently point to the existence of a finish line.

Where the UK paper falls short

The central weakness of the UK paper is that it identifies the right problems without explaining what satisfactory solutions would look like. Developers are told to establish product identity, critical quality attributes, potency, batch consistency, analytical suitability, and stability.

Those are appropriate expectations. They are also the same issues already keeping the field awake at night.

• What constitutes adequate identity for a complex microbial community?

• How much compositional variation can occur before one batch becomes meaningfully different from another?

• Should potency be measured through viable cell count, community composition, metabolic function, ecological activity, mechanism, or a combination of these?

• How should a company demonstrate stability when the relative abundance and activity of organisms can shift during storage?

• What level of sequencing is sufficient?

• Which organisms, genes, metabolites, or functional characteristics require release specifications?

• When does a manufacturing change create a comparability problem?

The position paper gives few answers.

This is problematic because the new category includes products with fundamentally different properties.

A single cultured bacterial strain can often be identified and quantified through established methods. A defined consortium adds interaction effects and compositional complexity. A donor derived ecosystem introduces biological variation across donations and donors. A nonviable microbial preparation raises different questions about active components and mechanisms.

Putting all of these products under one definition may be reasonable. Evaluating all of them through the same general statements is insufficient.

Clinical development needs far more attention

The paper concentrates heavily on manufacturing and broad safety principles. Clinical development receives less depth.

Microbiome trials require careful control of context.

Baseline microbiome composition may affect treatment response. Diet, antibiotics, bowel preparation, geography, age, disease severity, medications, and prior treatment can all influence the measured ecosystem.

A single sample before treatment and another after treatment may provide an incomplete picture of a dynamic biological system.

Developers need guidance on longitudinal sampling, baseline variability, colonization, persistence, functional activity, concomitant medication use, and the relationship between microbial changes and clinical outcomes.

A microbial shift is not automatically a therapeutic effect.

An organism appearing after treatment is not automatically evidence that it caused the clinical outcome.

A proprietary microbiome score is not automatically a validated endpoint.

The clinical program must connect the administered product to a reproducible biological effect and then connect that effect to a meaningful patient outcome.

The MHRA recognizes parts of this problem. It needs to turn that recognition into usable development standards.

Safety needs to extend beyond contamination

The paper emphasizes pathogens, toxins, infection, antimicrobial resistance, and horizontal gene transfer.

Living medicines create additional questions.

• Can the organisms persist after treatment ends?

• Can they be shed and transmitted to close contacts?

• Can they exchange genes with resident organisms?

• Could they expand differently in immunocompromised patients?

• Could their behavior change under later antibiotic exposure?

• Could a community that appears safe during manufacturing behave differently inside a disrupted intestinal ecosystem?

• How long should patients be followed?

• What surveillance is needed after authorization?

The FDA learned some of these lessons through serious adverse events associated with investigational fecal microbiota transplantation. Transmission of multidrug resistant organisms caused invasive infections, including a fatal case in an immunocompromised patient. The agency responded with more specific donor screening, testing, quarantine, and informed consent expectations. FDA safety communication

The UK should learn from that experience before similar events force reactive changes.

Scientific advice cannot replace public standards

The MHRA repeatedly encourages developers to seek early scientific advice.

That is sensible. Individual products will require individual judgment.

It also shifts too much regulatory knowledge into private meetings.

Large companies can hire experienced regulatory teams and repeatedly engage the agency. Academic investigators and smaller biotechnology companies may have fewer resources and less access to accumulated regulatory experience.

When essential expectations are communicated primarily through private interactions, every developer has to rediscover the pathway.

A mature framework should make more of that knowledge public.

What the MHRA should do next

The position paper should become the beginning of a guidance program.

First, the MHRA should publish separate technical annexes for major product classes. Individual strains, defined consortia, donor derived ecosystems, engineered organisms, and nonviable microbial products require different standards.

Second, it should provide a classification decision framework. Developers need to understand when a product will be treated as a biological medicine, an advanced therapy medicinal product, or another category.

Third, it should publish development stage expectations for manufacturing and controls. Early trials may reasonably use evolving specifications. Pivotal studies and marketing applications require much tighter validation and control.

Fourth, it should define acceptable potency strategies. A product should have a measure that reflects relevant biological activity rather than composition alone. The framework should acknowledge that different product classes may require different combinations of identity, viability, composition, and function.

Fifth, it should create microbiome specific clinical trial guidance. That guidance should address baseline variability, longitudinal sampling, diet, medication exposure, antibiotics, engraftment, persistence, functional measurements, clinical endpoints, and responder analyses.

Sixth, it should establish clearer expectations for shedding, transmission, gene transfer, vulnerable populations, long term monitoring, and environmental risk.

Seventh, it should explain how conventional FMT access will evolve as licensed products become available. Unlicensed preparations and authorized products currently operate under different evidentiary standards. That tension will become more important as the market develops.

Finally, the MHRA should publish anonymized regulatory examples and recurring lessons from scientific advice. Developers should be able to learn from earlier programs without requiring access to confidential company information.

A good first step is still a first step

The UK position paper deserves credit.

It recognizes microbiome therapeutics as a legitimate medicinal product category. It acknowledges the scientific limitations of conventional development models. It places manufacturing, variability, potency, safety, and clinical evidence at the center of the regulatory discussion.

That is progress.

The paper also reveals how far the field still has to go.

Microbiome therapeutics do not primarily suffer from a lack of biological possibility. They suffer from difficulty defining, manufacturing, measuring, and reproducing the product responsible for that possibility.

The UK has now said that these therapies can become medicines.

Its next responsibility is to explain, in practical and public terms, how good microbiome science becomes an approvable microbiome product.

Regulatory permission creates opportunity.

Regulatory predictability creates medicines.

That distinction is central to Better Microbiome Thinking. A plausible mechanism is one level of evidence. A measurable and reproducible product is another. A successful controlled trial adds more. A licensed product with demonstrated clinical benefit is the standard the field ultimately has to reach.

Read the UK position paper and use the Better Microbiome Thinking Framework to separate regulatory enthusiasm, scientific plausibility, product quality, and demonstrated patient benefit.

Subscribe now

Microbiome tests can find bacteria. Personalized diet reports often ask those results to predict an entire biological chain the assay never measured.

In February 2026, researchers from the National Institute of Standards and Technology published an evaluation of seven consumer gut microbiome testing services. They purchased three kits from each company and filled all 21 kits with the same homogenized human fecal material. The companies were unaware of the experiment until every report had been returned.

The number of identified genera ranged from 34 to 906. Three companies reported that Clostridioides difficile was present. Four reported that it was absent. One company classified two replicates as healthy and another replicate from the same material as unhealthy. For 17 of the 18 genera examined statistically, variability introduced by the testing methods either exceeded the biological variability among different donors or could not be distinguished from it.

The study did not establish which company was closest to the true microbial composition. It showed that the testing method could create as much variability as the biology being measured.

That finding raises an immediate problem for personalized nutrition. If companies produce different taxonomic profiles from the same material, their conclusions about microbial function can also differ. Dietary recommendations built upon those conclusions move even farther away from what was directly measured.

Microbiome testing is not one technology

The phrase microbiome test hides several very different technologies. A company may use 16S ribosomal RNA gene sequencing, shotgun metagenomics, metatranscriptomics, or some combination of molecular measurements.

These methods answer different questions. Calling all of them microbiome testing creates the impression that they provide interchangeable information.They do not.

What 16S sequencing measures

A 16S test amplifies and sequences selected regions of the bacterial 16S ribosomal RNA gene.

The method can provide a relatively inexpensive survey of bacterial and archaeal community composition. Depending on the amplified region, sequencing depth, reference database, and analysis pipeline, it may identify organisms at the family or genus level. Species resolution is often limited.

It also introduces amplification bias. Different organisms can carry different numbers of the 16S gene. Primer selection affects which organisms are detected. Fungi and viruses are generally outside the ordinary bacterial 16S analysis.

Most importantly, 16S sequencing does not directly measure the genes responsible for microbial metabolism.

Software can infer possible functions by comparing the detected organisms with reference genomes. That remains an imputation. The actual functional genes in the sample were not sequenced.

A 2024 benchmark evaluated 16S based functional prediction using matched 16S and shotgun metagenomic data from cohorts involving type 2 diabetes, colorectal cancer, and obesity. The investigators found that commonly used inference tools generally lacked the sensitivity required to identify health related functional changes reliably.

A company using 16S data may still produce pages of predicted pathways. Consumers need to understand that these functions were inferred from taxonomic relatives in a database.

They were not directly measured in the customer’s sample.

Shotgun sequencing is metagenomics

Shotgun testing and metagenomics are sometimes described as separate approaches. In this context, shotgun sequencing usually means shotgun metagenomic sequencing.

Instead of amplifying one marker gene, shotgun metagenomics sequences DNA fragments from across the collective genomes in the sample.

This can provide greater taxonomic resolution than 16S sequencing. With adequate sequencing depth and appropriate reference databases, it may identify species, strains, genes, and metabolic pathways.

Shotgun metagenomics therefore tells us more about the genetic capacity of the community.

It can reveal whether genes associated with fiber fermentation, bile acid transformation, vitamin synthesis, antibiotic resistance, or short chain fatty acid production are present.

Presence is still only functional potential.

A gene can be present without being expressed. An organism can carry a metabolic pathway without using it under the conditions present in the gut. Several organisms may carry the same pathway while contributing very different amounts of activity.

NIST describes metagenomic measurement as a chain involving sample collection, DNA extraction, library preparation, sequencing, database selection, computational analysis, and reporting. Bias introduced at any point can alter the final result.

Shotgun metagenomics moves closer to function than 16S profiling. It still does not directly show which genes were active when the sample was collected.

Metatranscriptomics measures microbial gene expression

Metatranscriptomics examines RNA rather than DNA.

DNA tells us which genes are available. RNA provides evidence about which genes were being transcribed.

The laboratory extracts RNA from the microbial community, converts it into complementary DNA, sequences it, and assigns the resulting reads to organisms and functions. This can reveal which microbes are transcriptionally active and which metabolic pathways are being expressed.

A paired analysis of the human gut metagenome and metatranscriptome found that 41 percent of microbial transcripts showed expression proportional to their genomic abundance. The remaining transcripts showed evidence of regulation relative to the amount of DNA present.

Some pathways were consistently expressed above their genomic abundance. Others were expressed below it. The transcriptional profiles were also more individualized than the DNA level functional profiles.

A larger study examined 372 fecal metatranscriptomes and 929 metagenomes from 308 people. It found a core group of microbial functions that was transcribed across individuals, often by different microorganisms. It also identified a variable set of specialized functions whose expression differed among people and among organisms.

This is functional redundancy in action.

Two people can carry different bacterial species while maintaining similar microbial functions. Conversely, two people can carry similar organisms while those organisms express different genes.

A missing organism does not automatically mean a missing function.

The presence of a supposedly beneficial organism does not prove that it is performing the expected function.

That is why a taxonomic list alone is such a poor foundation for confident dietary instructions.

RNA still does not tell us the entire story

Metatranscriptomics provides a more direct view of microbial activity than DNA sequencing. It is still a snapshot.

RNA is less stable than DNA. Collection, preservation, shipping time, extraction, ribosomal RNA depletion, sequencing depth, and analysis methods can affect the measurement.

An RNA transcript also does not guarantee that a functional protein was produced.

It does not show how much substrate entered the pathway.

It does not establish the rate at which the reaction occurred.

It does not prove that the final metabolite accumulated, entered the circulation, reached a host tissue, or produced a health benefit.

Metatranscriptomics measures gene expression. It does not directly measure metabolic flux or clinical effect.

Proteins and metabolites move closer to actual function

Metaproteomics attempts to measure the proteins and enzymes produced by the microbial community.

This moves another step beyond gene expression because proteins perform much of the biochemical work encoded by microbial genes. Metaproteomic measurements remain technically difficult because stool contains an extremely complex mixture of microbial, dietary, and host proteins.

Metabolomics measures small molecules produced or modified through microbial, dietary, and host metabolism.

These may include short chain fatty acids, bile acids, indoles, amino acid derivatives, lipids, and other compounds.

In a study of 786 people, researchers measured 1,116 fecal metabolites. Microbial composition explained an average of 67.7 percent of the variation in the fecal metabolome. That finding shows a strong relationship between microbial composition and metabolic output.

It also leaves considerable variation unexplained.

Even metabolite measurement requires careful interpretation.

A fecal metabolite can reflect microbial production, microbial consumption, dietary intake, host secretion, intestinal absorption, and transit time. A low fecal concentration might indicate low production. It could also indicate rapid absorption or further microbial conversion.

Blood and fecal measurements can tell different stories. A study of 1,007 adults found different associations between microbial features and simultaneously measured fecal and blood metabolites.

The location of the measurement matters. Stool reflects what remained in the intestinal lumen and was excreted. It is not a direct measurement of everything produced or absorbed throughout the gastrointestinal tract.

The functional evidence ladder

The evidence becomes progressively more informative as the measurement moves from composition toward biological effect.

1. A 16S profile asks which bacterial groups appear to be present.

2. Shotgun metagenomics asks which organisms and genes are present.

3. Metatranscriptomics asks which microbial genes are being expressed.

4. Metaproteomics asks which proteins and enzymes were produced.

5. Metabolomics asks which chemical products are detectable.

6. Host measurements ask what happened in the person.

7. Clinical trials ask whether an intervention changed an outcome that matters.

Every level adds information. Each level also has its own sources of error and uncertainty.

A company cannot leap from the first or second level to the final level simply by putting the results into a colorful report.

Consider butyrate

A report might identify Faecalibacterium and classify it as beneficial because members of this genus can produce butyrate. The report may then recommend foods intended to increase Faecalibacterium.

Several assumptions are hidden inside that recommendation.

• The assay must identify and quantify the organism reliably.

• The detected strain must carry the relevant pathway.

• The pathway must be expressed.

• The organism must receive the substrates required to perform the reaction.

• Ecological partners needed for cross feeding must be present and active.

• Butyrate must be produced at a meaningful rate.

• The host must absorb and respond to it.

• The recommended food must change this process in a beneficial way.

Measuring the relative abundance of one genus establishes very little of that chain.

Finding a butyrate synthesis gene provides additional evidence of capacity.

Detecting its RNA provides evidence of expression.

Measuring butyrate provides evidence that the metabolite is present.

A controlled intervention is still required to establish that the recommendation improved health.

Personalized nutrition research shows the same problem

The ZOE METHOD trial randomly assigned 347 adults to an 18 week personalized program or standard dietary guidance. The personalized program combined microbiome data with glucose responses, triglyceride responses, health history, food characteristics, education, and lifestyle guidance.

Triglycerides, body weight, waist circumference, HbA1c, and diet quality improved more in the personalized group. LDL cholesterol did not differ significantly.

The personalized group also consumed fewer calories and reported greater adherence.

The trial supports the potential value of a comprehensive personalized nutrition program. It cannot isolate how much benefit came from microbiome data, metabolic measurements, behavioral support, caloric reduction, or greater adherence.

The study was funded by ZOE, and numerous authors disclosed financial relationships with the company.

The PREVENTOMICS trial enrolled 193 adults and incorporated measurements related to metabolism, inflammation, oxidative stress, genetics, and the microbiota. After adjustment for multiple comparisons, personalized recommendations did not improve dietary habits or general health measures beyond standard Mediterranean diet recommendations.

An open label randomized trial involving 802 people with prediabetes found no significant overall differences in glycemic outcomes between the fiber and usual care groups. Subsequent subgroup analyses found benefits in two of four metabolic clusters. The researchers then developed a microbiome based response score and tested it in two smaller cohorts involving people with type 2 diabetes.

The result is promising. Prospective validation in larger and more diverse prediabetes populations is still required before this becomes a broadly applicable consumer recommendation system.

My position

A 16S report can describe part of the bacterial community.

A shotgun metagenomic report can describe organisms, genes, and functional potential.

A metatranscriptomic report can provide evidence of microbial gene expression.

None of these measurements alone establishes that a personalized dietary recommendation will improve a person’s health.

Companies making functional claims should

• State which functions were measured directly, which were inferred computationally, and which were extrapolated from research involving other people, products, or methods.

• Demonstrate that the microbiome measurement improves recommendations beyond symptoms, dietary history, medications, blood measurements, and established nutritional guidance.

Until that evidence exists, a personalized microbiome diet should be presented as an experiment.

It should not be sold as an answer.

A microbiome report can look more precise than the science beneath it.

You send a stool sample to a laboratory. A few weeks later, a polished dashboard appears. It assigns you a diversity score. It ranks your gut against other people. It highlights helpful and disruptive bacteria. It estimates whether your microbes can produce butyrate, digest fiber, synthesize vitamins, or support your immune system. Then it tells you what to eat and which supplements to buy.

The experience feels medical. The report is filled with percentages, scientific names, reference ranges, and color-coded warnings. Yet every number has passed through a long chain of decisions involving collection, preservation, DNA or RNA extraction, sequencing, database selection, computational filtering, statistical modeling, and commercial interpretation.

The laboratory may have measured something real. The dashboard can still imply far more than the measurement proves.

This guide will walk through the major sections of a consumer microbiome report and answer five questions for each one.

What is this result

How was it calculated or estimated

How is it usually displayed

How statistically and biologically robust is it

What can you reasonably do with it

The goal is neither reassurance nor panic. The goal is accurate interpretation.

First understand what kind of test you purchased

Before interpreting any score, find the methods section of the report. If the report does not identify the laboratory method, sequencing platform, reference database, and analytical pipeline, you are missing information that directly affects every result that follows.

Most consumer gut microbiome tests use one of three broad approaches.

16S ribosomal RNA gene sequencing

This method amplifies and sequences selected regions of a marker gene found in bacteria and archaea. The resulting sequences are grouped or resolved into features, often called operational taxonomic units or amplicon sequence variants. Those features are compared with reference databases to assign taxonomic names.

This is a useful and widely used research method. It is also narrower than many consumer reports make it appear.

The assay targets only selected regions of one gene. Primer choice affects which organisms amplify efficiently. Different bacterial species can share similar marker regions. A single species can carry multiple copies of the gene. Database choice and classification settings affect the names assigned. Many results can be resolved confidently only to the genus level, and an amplicon sequence variant is not automatically equivalent to a biological species. [1, 2]

If a 16S report confidently names strains, predicts detailed functions, or presents precise clinical meaning, the interpretation has moved well beyond the direct measurement.

Shotgun metagenomic sequencing

Shotgun metagenomics sequences DNA across the sample rather than targeting one marker gene. It can provide greater taxonomic resolution and can identify microbial genes associated with metabolic pathways, antibiotic resistance, or virulence. Depending on the workflow, it may capture bacteria, archaea, fungi, and viruses.

The phrase sequences all DNA can create the wrong impression. A laboratory sequences a sample of DNA fragments at a particular depth. Host DNA, extraction bias, genome size, database coverage, and computational classification still shape the output. Closely related strains can remain difficult to distinguish. A detected gene may belong to several possible organisms. A resistance or virulence gene can be present without being expressed.

Shotgun data can support a stronger description of functional capacity than 16S data. Capacity still differs from activity, metabolite production, and a health effect in the person who supplied the sample. [2, 3]

Metatranscriptomic sequencing

Metatranscriptomics sequences microbial RNA transcripts. It can estimate which genes were being transcribed when the sample was collected and preserved. That offers a view closer to microbial activity than DNA alone.

RNA creates its own interpretive problems. Transcript levels are sensitive to collection and preservation. RNA abundance does not guarantee that a functional protein was produced. Protein production does not guarantee a metabolite reached a meaningful concentration. A metabolite in stool does not automatically reveal how much was produced, absorbed, used by other microbes, or delivered to host tissue.

The scientifically accurate ladder is straightforward.

DNA supports functional capacity.

RNA supports gene expression.

Proteins support biochemical machinery.

Metabolites support chemical output.

Validated human outcomes support health meaning.

A report that leaps from an RNA pathway to a conclusion about energy, inflammation, or mental health has skipped several evidentiary steps.

Section 1. Your microbial diversity score

Diversity is usually the first major result because it compresses a complicated ecosystem into one number. It is easy to display, easy to rank, and easy to market.

It is also one of the easiest results to overinterpret.

What alpha diversity measures

• Alpha diversity describes diversity within one sample. It can represent several related ideas.

• Richness describes how many distinct microbial features were detected.

• Evenness describes how evenly the reads are distributed across those features.

• Phylogenetic diversity describes how much evolutionary breadth is represented.

These ideas overlap, although they are not interchangeable. A community can contain many detected features while remaining dominated by one organism. Another community can contain fewer features distributed more evenly. The two samples may receive different rankings depending on the metric selected. [4]

How common alpha diversity metrics are calculated

Observed richness is a direct count of detected features after the company applies its filtering rules. The features might be species, genera, operational taxonomic units, or amplicon sequence variants. A report should state which.

The Shannon index combines richness and evenness. It gives increasing weight to both the number of features and the distribution of their relative abundances. The result is an entropy value rather than a percentage of health. A score of four is not twice as healthy as a score of two.

The Simpson family of indices emphasizes dominance. One version estimates the probability that two randomly selected observations belong to the same feature. Reports may display the Simpson index, one minus the Simpson index, or the inverse Simpson index. Those versions run in different directions. A higher value can mean higher diversity in one report and lower diversity in another.

Chao1 estimates richness by using rare features, particularly features observed once or twice, to estimate how many features may have escaped detection. This makes it sensitive to sequencing depth, filtering, and sequencing error. Some current methodological guidance questions its use in sparse amplicon sequence variant data because the rare observations driving the calculation can be technically unstable. [4, 5]

Faith phylogenetic diversity adds the branch lengths represented on a phylogenetic tree. Two samples with the same number of detected features can differ if one sample covers a wider evolutionary range.

If your report says only diversity score, the number is incomplete. You need the metric, the feature definition, the sequencing depth, the filtering approach, and the reference population.

How diversity is displayed

Companies commonly show one or more of the following.

• A percentile showing where your score falls within a reference group

• A dial that runs from poor to optimal

• A color band labeled low, average, or high

• A comparison with other customers

• A component folded into a composite gut health score

The percentile is mathematically understandable if the reference group is clearly defined. The health interpretation remains a separate question.

Being at the 20th percentile means your value was higher than roughly twenty percent of that comparison group under that company’s method. It does not mean your gut is twenty percent healthy. It does not establish disease risk. It does not identify the cause of the result.

Does higher diversity mean better health?

Higher gut alpha diversity has been associated with several favorable health patterns in population studies. Lower diversity has also appeared in some conditions and after certain antibiotic exposures. In a longitudinal study of eighty five adults sampled weekly for three months, people with more diverse gut communities tended to show greater compositional stability. [6]

Those findings support diversity as an ecological descriptor and a possible contextual marker.

They do not make diversity a universal health score.

Ecologists have warned directly against treating higher diversity as inherently better. Diversity can have different meanings across body sites, life stages, diets, diseases, and ecological states. Even within the gut, the same diversity value can arise from very different organisms and functions. A rigorous null result can coexist with meaningful taxonomic or functional differences that the diversity score compresses away. [7]

A median or above median score does not rule out a gastrointestinal disorder. A low score does not diagnose dysbiosis. Neither result tells you which intervention will improve your health.

Where the data are robust

Alpha diversity is scientifically meaningful when the metric is named, sequencing depth and quality controls are adequate, samples are processed using the same workflow, and the result is compared with an appropriate population. It can be useful in research comparisons and longitudinal monitoring when collection and analysis are consistent.

Where the data are stretched

The data are stretched when a company turns one diversity value into a global grade of metabolic health, immune strength, resilience, inflammation, or disease risk.

They are also stretched when the report presents a universal normal range, hides the metric, compares values generated through different methods, or claims that a specific food or supplement will correct the score.

Weekly variation is real, and the amount differs substantially among people and metrics. Research supports that variability. It does not support one universal weekly percentage for every test. [6]

What to do with your diversity result

Use it as context. Record the metric and the reference group. Check whether recent antibiotics, bowel preparation, acute illness, major diet changes, or unusual stool consistency could have affected the sample.

If you repeat the test, use the same company and follow the same collection conditions as closely as possible. Even then, a change in score requires context before it becomes a health conclusion.

Section 2. Beta diversity and your distance from other people

Some reports show how similar your sample is to other samples. This is beta diversity.

Alpha diversity asks how much variety exists within one sample. Beta diversity asks how different two samples or groups are from each other.

How beta diversity is calculated

Bray Curtis dissimilarity uses abundance information. It becomes larger as the relative composition of two samples becomes more different.

Jaccard distance uses presence and absence. Two samples appear more similar when they share more detected features, regardless of the abundance of those features.

UniFrac uses phylogenetic relationships. Unweighted UniFrac focuses on whether evolutionary branches are present. Weighted UniFrac also incorporates abundance.

Each metric asks a different ecological question. The same sample can appear close to a reference group under one metric and farther away under another.

How beta diversity is displayed

The most common display is a principal coordinates analysis plot. Each dot represents a sample. Dots positioned close together are more similar under the selected distance metric. The axes represent mathematical dimensions that capture portions of the observed variation.

A dot on the edge of a cluster can look alarming. That visual distance is not automatically a clinical abnormality. The plot may be influenced by diet, age, geography, medications, stool consistency, sequencing batch, and the composition of the reference group.

In research, investigators can test whether groups differ using methods such as permutational analysis of variance. That is a group level statistical question. It does not transform the position of one consumer into a diagnosis.

Where the data are robust

Beta diversity is useful for comparing samples processed together and for visualizing broad patterns. It can reveal whether an intervention, disease group, geographic population, or repeated sample differs in overall community composition.

Where the data are stretched

The data are stretched when distance from a company’s healthy cluster becomes a personal disease score or treatment target. Statistical separation between groups can exist even when groups overlap heavily and the difference explains only a small fraction of total variation.

Your dot can be unusual without being unhealthy. It can be close to a reference group without proving that your gut is healthy.

Section 3. Relative abundance and taxonomic composition

The taxonomic section is usually the visual center of the report. It may contain stacked bar charts, pie charts, ranked lists, and dozens or hundreds of microbial names.

This section answers a narrow question.

Among the microbial sequences classified by this workflow, what proportion was assigned to each taxon

How relative abundance is calculated

After sequencing and quality control, reads are assigned to taxonomic groups. The number assigned to each group is divided by the total number included in the analysis. The resulting percentages sum to one hundred.

That final sentence contains the central limitation.

Relative abundance is compositional. Every percentage depends on every other percentage. If one organism expands, the percentage assigned to another can fall even when the second organism’s absolute count stays the same. Two samples can show the same percentages while containing very different total microbial loads. [8, 9]

Imagine a sample with ten units of organism A and ninety units of everything else. Organism A represents ten percent. Now imagine a second sample with one hundred units of organism A and nine hundred units of everything else. Organism A still represents ten percent. The biological quantity changed tenfold while the relative abundance remained identical.

The reverse distortion also occurs. A taxon can rise from five percent to ten percent because neighboring taxa declined, even if the taxon itself never increased.

Absolute profiling methods can add information through cell counting, quantitative polymerase chain reaction, digital polymerase chain reaction, or reference standards. Most consumer reports still emphasize relative values.

Taxonomic level matters

Phylum is broad. Genus is narrower. Species is narrower still. Strain can matter for metabolism, virulence, and therapeutic effects.

A genus level result cannot automatically support a species level conclusion. A species name cannot automatically support a strain level function.

This is particularly important for genera that contain organisms with very different biological properties. A report may group harmless commensals, potential pathogens, and poorly characterized members under one higher taxonomic label.

The Firmicutes and Bacteroidetes trap

Firmicutes and Bacteroidetes often represent large portions of adult fecal bacterial communities. Their exact proportions vary widely across healthy people, methods, geography, diet, and time.

The ratio between them became popular because it reduced a complex ecosystem to a simple story about obesity and gut health. That story did not hold up as a universal biomarker.

The international consensus statement on microbiome testing discourages reporting the Firmicutes to Bacteroidetes ratio. It also states that there is generally insufficient information for strict healthy reference ranges of species relative abundance. [10]

If your report places this ratio at the center of its interpretation, you are looking at an idea whose marketing life has exceeded its clinical value.

The Proteobacteria warning light

An elevated proportion of Proteobacteria has been associated with inflammation and ecological disturbance in some studies and contexts. That supports a research signal.

It does not establish a universal ten percent threshold for gut inflammation.

The measured value depends on taxonomic definitions, sequencing methods, total community composition, and the person being tested. Some members have different biological roles from others. A phylum level percentage is far too broad to diagnose low grade inflammation in one individual.

Where the data are robust

Relative abundance can describe the sample under the company’s workflow. It can identify dominant groups, show broad community structure, and generate hypotheses. Repeated samples processed consistently can reveal directional changes, although biological and technical variation still need consideration.

Where the data are stretched

The data are stretched when a percentage becomes an absolute bacterial count, a cause of symptoms, an inflammatory diagnosis, or a precise target for manipulation.

They are stretched again when phylum or genus data are assigned strain specific functions.

Section 4. Beneficial bacteria and disruptive organisms

Reports often sort microbes into friendly categories. Beneficial bacteria appear in green. Disruptive or harmful organisms appear in red. This format is intuitive and scientifically dangerous.

Microbes behave within ecosystems. Their effects can depend on strain, abundance, location, available nutrients, host condition, microbial neighbors, and immune context.

Akkermansia muciniphila

Akkermansia muciniphila is a mucin associated organism that has been linked with metabolic and barrier related outcomes in observational and mechanistic research. A small randomized proof of concept study tested supplementation in overweight or obese insulin resistant adults and supported safety while reporting exploratory metabolic findings. [11]

That evidence makes Akkermansia scientifically interesting.

A low relative abundance in one consumer sample does not prove that the intestinal barrier is unsupported. A high value does not certify metabolic health. The sequencing result may not provide strain resolution, absolute abundance, mucosal location, or functional activity.

Faecalibacterium prausnitzii

Faecalibacterium prausnitzii is frequently associated with butyrate production and has been reported at lower relative abundance in some inflammatory and metabolic conditions. It is also biologically diverse, sensitive to oxygen, and embedded in cross feeding networks.

A report can reasonably describe it as an organism of scientific interest with associations across several studies.

It cannot infer your butyrate production from its percentage alone. Butyrate production depends on diet, substrate availability, strain level capacity, microbial interactions, intestinal transit, production by other organisms, and host absorption.

The problem with beneficial and harmful labels

These labels usually compress several evidence levels.

An organism may produce a useful metabolite in culture.

Its abundance may correlate with health in a cohort.

A strain may improve an endpoint in an animal.

A separate strain or formulation may have been tested in humans.

The consumer report may then label the entire species beneficial.

That progression turns context dependent evidence into a universal identity. The scientific name creates precision while the interpretation loses it.

How to read organism cards

Ask six questions.

1. What taxonomic level did the test actually resolve?

2. Is the reported value relative or absolute?

3. Is the claimed function measured, predicted, or borrowed from published studies?

4. Does the cited evidence involve the same species or strain?

5. Was the association replicated in relevant human populations?

6. Has changing this organism improved a meaningful outcome?

The last question is often where the evidence runs out.

Section 5. Pathogen flags

A pathogen flag feels like the most urgent result in the report. It can also be one of the most misleading.

Sequencing can detect DNA associated with an organism. Clinical infection requires context that may include symptoms, organism viability, virulence factors, toxin production, anatomical site, abundance, and confirmation with a validated diagnostic method.

Clostridioides difficile

People can carry Clostridioides difficile without having an active infection. Clinical guidelines define infection through compatible symptoms together with evidence of toxigenic organisms or toxin, using validated testing algorithms. The 2021 focused update revised treatment recommendations while the diagnostic guidance from the 2018 guideline remains applicable. Asymptomatic testing is generally discouraged. [12]

A broad microbiome report that detects sequence fragments associated with the organism has not diagnosed infection.

The 2026 analytical performance study gives this warning real force. Identical standardized material was sent to seven consumer testing services. Three reported that C. difficile was present. Four reported that it was absent. [13]

That disagreement involved the same material.

If your consumer report flags this organism and you have significant or persistent diarrhea, recent antibiotic exposure, fever, dehydration, blood in stool, severe abdominal symptoms, or other risk factors, contact a healthcare professional. A validated clinical evaluation should determine what the finding means.

Helicobacter pylori

Helicobacter pylori primarily colonizes the stomach. Validated clinical approaches include urea breath testing, fecal antigen testing, and gastric biopsy in appropriate settings. [14]

Detection through a broad microbiome sequencing report is not interchangeable with a validated clinical assay. A positive or negative consumer result should not be used to start therapy, exclude infection, or confirm eradication.

Parasites

Parasitic diagnosis depends on the suspected organism, symptoms, travel, exposure history, immune status, sample collection, and the diagnostic method. The Centers for Disease Control and Prevention notes that diagnosis can require multiple samples and different methods, including microscopy, antigen tests, molecular assays, blood tests, or tissue based evaluation. [15]

A general microbiome report may screen for only a subset of organisms. Its preservation method and analytical pipeline may not be validated for clinical parasite detection.

Where pathogen data are robust

A validated targeted assay used in the appropriate symptomatic population can support clinical diagnosis. Broad sequencing can also generate a hypothesis that deserves confirmation.

Where pathogen data are stretched

The data are stretched when detection of DNA becomes proof of active infection, when absence becomes proof that infection is excluded, or when a consumer report recommends antimicrobial treatment.

Section 6. Functional pathways and metabolic potential

Functional sections are often the most impressive part of the report. They may rank starch degradation, fiber fermentation, vitamin synthesis, short chain fatty acid production, methane metabolism, neurotransmitter pathways, inflammation, and dozens of other categories.

The key question is where each result sits on the functional ladder.

Function inferred from 16S data

16S sequencing does not directly read functional genes. Tools such as PICRUSt2 predict functional potential by placing marker sequences into a reference framework and borrowing gene content from related genomes. The developers explicitly note that functional profiles cannot be directly identified from 16S data because strains can differ in gene content. [16]

These predictions can be useful for group level research and hypothesis generation, especially when reference genomes are close to the organisms detected.

For one person, a predicted pathway is an estimate layered on top of a taxonomic estimate. Precise dietary or clinical advice adds another layer.

Function detected through shotgun metagenomics

Shotgun sequencing can detect genes and pathways more directly. This provides evidence that the sampled community carries genetic capacity.

Capacity is not output.

A pathway may be incomplete. Genes may be assigned ambiguously. The organism carrying them may be inactive. The substrate may be absent. The genes may never be expressed. Other microbes may consume the product. The host may absorb it before it appears in stool.

Function estimated through RNA

RNA provides evidence that genes were being transcribed. This narrows the gap between capacity and activity, although it does not close it.

Metagenomic and metatranscriptomic studies show that genomic abundance and transcription often relate while retaining important differences. [17] Transcripts still sit upstream of protein activity, metabolite flux, and clinical outcomes.

Short chain fatty acid claims

Reports frequently estimate butyrate, acetate, or propionate production from microbial composition or pathway genes. These estimates should be described as potential.

Stool concentrations are also imperfect measures of production because they reflect microbial synthesis, microbial consumption, intestinal transit, host absorption, sample handling, and water content.

A low predicted butyrate pathway does not prove tissue deficiency. A high predicted value does not prove that the host received a benefit.

The NIST functional contradiction

In the 2026 study of consumer tests, one company reported three results from standardized replicates. Two replicates scored above average for starch breakdown. The third scored below average.

Across ten functional categories, the third replicate received seven below average classifications. The other two received one each, and that single category differed from the seven assigned to the third replicate. The company labeled two reports healthy and the third unhealthy. [13]

That is the same material becoming three different biological stories.

Where functional data are robust

Functional data are strongest when the method directly measures the relevant molecular layer, quality controls are clear, the pathway is well annotated, results are reproducible, and the interpretation stays at the measured level.

Where functional data are stretched

The data are stretched when predicted genes become actual metabolic output, when transcripts become host benefit, or when a pathway score becomes evidence that a symptom has been explained.

Section 7. Reference groups and healthy comparisons

Your result becomes high, low, typical, or unusual only after it is compared with something.

That comparison group may be one of the most important and least transparent parts of the report.

Internal company cohorts

An internal cohort may consist of recruited volunteers, prior customers, or a subset the company considers healthy.

The advantage is methodological consistency. If the reference samples used the same collection kit, extraction procedure, sequencing method, and computational pipeline, technical comparability can improve.

The weakness is representativeness. Prior customers may be people who purchased a microbiome test because they had symptoms or health concerns. A company may provide little information about age, geography, medications, stool consistency, diagnoses, diet, pregnancy, or how healthy status was determined.

External research cohorts

Companies may compare customers with public projects such as the Human Microbiome Project or American Gut.

These datasets can be large and scientifically valuable. They may also have different recruitment criteria, collection methods, sequencing regions, extraction protocols, databases, and processing pipelines.

A larger reference group does not fix a mismatched method.

The NIST researchers explained this problem directly. Comparisons with external datasets can combine biology and methodology, and sometimes methodology alone can create the apparent difference. In their analysis, methodological variance was smaller than biological variance for only one of eighteen genera evaluated. [13]

Age and life stage matching

Age matters, particularly during infancy, childhood, pregnancy, and older adulthood. Geography, diet, medications, body mass, bowel transit, and health conditions also matter.

Age matching improves a reference group. It does not make the reference clinically validated. A useful comparator needs both methodological compatibility and biological relevance.

How reference results are displayed

A percentile ranks your value within the reference distribution.

An interquartile range shows the middle half of the reference values.

A standard score reports distance from the reference mean in units of standard deviation, assuming the method and distribution make that calculation appropriate.

A healthy range may represent a statistical interval, an expert selected interval, or a proprietary threshold.

Those are different constructions.

In the NIST study, the average value used by one company fell outside the healthy interquartile range used by another for four of five selected genera. [13]

Your normal result can therefore depend on which company built the normal.

Questions your report should answer

• How many people are in the reference group?

• How was health defined?

• Which ages, regions, diets, medications, and conditions are represented?

• Were reference samples processed with the same workflow?

• Are the thresholds published and externally validated?

• Does the reference predict a meaningful health outcome?

If the company cannot answer these questions, the colored range is a design feature with uncertain clinical meaning.

Section 8. Composite gut health and dysbiosis scores

A composite score converts multiple measurements into one number. The company may combine diversity, selected taxa, predicted functions, and distance from a reference cohort. Each component can be assigned a weight, transformed, capped, or converted into categories.

The arithmetic can be perfectly real while the health meaning remains unvalidated.

How composite scores are built

A transparent score should disclose its components, weights, direction, reference population, missing data rules, repeatability, and validation.

It should also answer a more important question.

What outcome does the score predict

A score can reliably reproduce itself and still fail to predict symptoms, disease, treatment response, or future health. That is the difference between analytical validity and clinical validity.

Clinical utility requires another step. Using the score must improve a decision or outcome compared with available alternatives.

What the consensus says

The international expert panel concluded that evidence remains insufficient for including dysbiosis indices in microbiome reports. The panel also discouraged strict healthy reference ranges for species abundance and discouraged post testing therapeutic advice from testing providers. [10]

That does not mean every score is random. It means the field lacks a broadly validated clinical interpretation that supports the certainty these scores often communicate.

The three questions to ask

1. Is the score reproducible when the same sample is tested again?

2. Has the score been validated in an independent population?

3. Does acting on the score improve a meaningful outcome?

Most marketing pages answer a different question.

Does the score feel understandable?

That is a user experience achievement, not clinical validation.

Section 9. Food, probiotic, and supplement recommendations

The recommendation section is where description becomes intervention.

This transition requires stronger evidence than the rest of the report because people act on it. They restrict foods. They add supplements. They spend money. They interpret symptoms through the dashboard.

General healthy advice

Recommendations to eat a varied diet rich in tolerated plant foods, meet established fiber needs, exercise, sleep adequately, avoid smoking, and use antibiotics appropriately can align with broader health evidence.

The microbiome result may have contributed little to that advice.

If a recommendation would have been offered to almost every customer, it is general guidance wearing personalized clothing.

The 30 plants claim

The American Gut citizen science project reported associations between the diversity of plants consumed and microbiome features. The widely repeated thirty plants per week target grew from comparisons that included people reporting more than thirty types and people reporting fewer than ten. [18]

This was an observational, self selected citizen science dataset. It supports the idea that dietary variety relates to microbiome variation. It does not establish thirty as a biological threshold or prove that reaching that number will correct a low diversity score.

Plant variety can be a practical food planning goal for people who tolerate it. People with allergies, inflammatory bowel disease, strictures, active gastrointestinal symptoms, eating disorders, kidney disease, or other clinical constraints may need individualized advice.

Targeted foods for targeted bacteria

A company may recommend pomegranate for Akkermansia, resistant starch for butyrate producers, or a particular fiber for Bifidobacterium.

Diet can influence microbial composition and metabolism. The response is shaped by the whole diet, dose, baseline community, transit, medication use, and host physiology.

Evidence that a food changes a taxon in a study does not prove that your reported low value caused a problem or that increasing the taxon will improve your outcome.

Probiotic recommendations

A probiotic recommendation requires a defined goal and evidence for the specific strain or strain combination, population, dose, duration, and outcome.

A report that recommends a probiotic because you have low Lactobacillus or Bifidobacterium has skipped the clinical question. Fecal abundance is not a direct inventory of every relevant intestinal niche. The probiotic may act transiently without permanently raising the reported taxon. Benefit can occur without colonization, and colonization does not guarantee benefit.

The report should also disclose whether the testing company sells the recommended product. That conflict does not make the product ineffective. It raises the standard for evidence and transparency.

Where recommendations are robust

Recommendations are strongest when prospective studies show that a test guided strategy improves a meaningful outcome compared with standard guidance.

Where recommendations are stretched

They are stretched when association becomes prescription, when a missing organism becomes a supplement deficiency, or when a predicted pathway becomes a dietary prohibition.

The international consensus panel discouraged therapeutic advice from testing providers under current evidence conditions. [10]

Section 10. The snapshot problem

A stool sample represents material leaving the gastrointestinal tract at one time. It reflects luminal communities more directly than microbes attached to intestinal tissue. It also contains undigested food, host cells, water, metabolites, and microbial material from different regions.

The report is a snapshot of that specimen after a particular workflow.

Biological variation

Gut communities can change with diet, bowel transit, illness, travel, medication use, antibiotic exposure, and other factors. Weekly sampling research shows that temporal variability differs substantially among people. [6]

Stool consistency is also associated with richness and composition, meaning a change in transit can alter the profile and complicate interpretation. [19]

Antibiotics can cause major disturbances, although the magnitude and recovery trajectory vary by antibiotic, starting community, diet, and individual. Some people recover much of the prior community over weeks or months. Some changes persist longer. Permanent loss cannot be assumed from one low score. [20]

Technical variation

Collection medium, storage temperature, shipping time, extraction chemistry, primer choice, sequencing depth, database version, and pipeline settings can change the result. Microbiome quality control studies have shown that technical workflows can introduce consistent and sometimes correctable bias. [21, 22]

The 2026 reality check

Researchers sent standardized NIST developed fecal material to seven consumer services, ordering three kits from each. Variability between providers was on the same scale as biological variability among different donors. One company labeled two standardized replicates healthy and another unhealthy. Three companies detected Clostridioides difficile and four did not. [13]

The study does have boundaries. The seven services do not represent every company. The material was a standardized fecal preparation rather than a normal bowel movement. The study assessed comparability and reproducibility rather than declaring one company correct.

Those limits do not weaken the central result.

Analytical performance must be demonstrated before a report can support confident health recommendations.

How to interpret your report from beginning to end

Use this process before changing your diet, supplements, or medical care.

Step 1. Identify the intended use

Does the company describe the test as education, wellness, research, risk prediction, diagnosis, monitoring, or treatment guidance?

The evidence requirement rises with the consequence of the claim.

Step 2. Identify the measurement

Record whether the test used 16S sequencing, shotgun metagenomics, RNA sequencing, targeted polymerase chain reaction, culture, metabolomics, or a combination.

Write down what was directly measured and what was modeled.

Step 3. Inspect the quality information

Look for sample quality criteria, sequencing depth, controls, unspecified reads, database names, pipeline versions, and repeatability data.

A company that publishes its methods gives you something to evaluate. A proprietary label is not a substitute for performance evidence.

Step 4. Read diversity as ecology

Find the metric and reference group. Treat the score as a summary of community structure under that workflow.

Avoid translating it directly into health, immunity, resilience, or disease risk.

Step 5. Read every percentage as relative

Ask what taxonomic level was actually resolved. Remember that all percentages depend on the rest of the community.

Avoid interpreting a change in percentage as a change in absolute bacterial count.

Step 6. Separate measured, predicted, and validated

Measured describes what the assay directly detected.

Predicted describes what a model inferred.

Associated describes what has correlated with an outcome in research.

Validated describes what has been shown to perform for a defined use in an appropriate population.

Most consumer reports move among these categories without announcing the transition.

Step 7. Examine the comparator

Ask who is in the reference group, how health was defined, and whether the same workflow was used.

A percentile without a transparent denominator is an attractive mystery.

Step 8. Confirm important flags

Any result suggesting infection, disease, severe deficiency, or treatment should be evaluated with an appropriate healthcare professional and confirmed using validated methods.

Step 9. Grade the recommendation

Ask whether the recommendation is general healthy advice, an association based suggestion, or a prospectively validated test guided intervention.

Those categories deserve different confidence.

Step 10. Define what would change your mind

If you act on a low risk recommendation, define the goal, duration, outcome, and stopping rule. Avoid chasing every score simultaneously.

What you can reasonably trust

A well performed consumer microbiome test may provide the following.

• A research style profile of microbial DNA or RNA in one stool sample

• Relative estimates of detected taxa under a defined method

• Diversity calculations when the metric and comparison are clear

• Functional capacity or expression estimates appropriate to the assay

• A basis for learning and generating questions

• A possible longitudinal signal when repeated under consistent conditions

Its value depends on transparency, analytical performance, and the restraint of the interpretation.

What requires stronger evidence

Treat the following conclusions as unproven unless the company provides direct validation for the defined use.

• Your microbiome is healthy or unhealthy

• A score explains your symptoms

• One organism is causing inflammation

• A low beneficial bacterium means your intestinal barrier is failing

• A detected pathogen proves active infection

• An absent pathogen rules out infection

• A predicted pathway proves metabolite production

• A food ranking is uniquely correct for you

• A recommended probiotic will correct your microbiome

• A change in the dashboard proves improved health

When to involve a healthcare professional

Seek professional evaluation when a report flags a potential pathogen, recommends treatment, triggers major dietary restriction, conflicts with existing medical care, or appears alongside significant symptoms.

Symptoms that deserve timely clinical attention include persistent or severe diarrhea, blood in stool, fever, dehydration, unexplained weight loss, severe abdominal pain, recurrent vomiting, black stool, anemia, or symptoms in an immunocompromised person.

A consumer microbiome report should never delay a validated diagnostic evaluation.

The Better Microbiome Thinking verdict

The claim

A consumer microbiome test can provide a meaningful personal interpretation of gut health and guide individualized action.

The best evidence

Sequencing can describe aspects of the microbial community in a stool sample. Diversity, taxonomic composition, and functional capacity are legitimate scientific measurements when methods and limitations are clear. Standardized reference materials and international consensus work are improving the field. [10, 13, 23]

The biggest limitation

Analytical variability, reference group uncertainty, biological heterogeneity, and limited clinical validation weaken the leap from a laboratory profile to a personal health conclusion.

Better Microbiome Thinking confidence

Useful with limits for education and hypothesis generation.

Exploratory for most personalized health recommendations.

Unsupported for diagnosis or treatment unless the specific test and intended use have been clinically validated.

What this changes

Read the report as a layered scientific interpretation. Give the most confidence to transparent direct measurements. Reduce confidence with every added layer of modeling, association, and recommendation. Confirm any clinically important conclusion with an appropriate validated method.

What Should You Do Next

A microbiome report becomes useful only when its findings are interpreted within the limits of the underlying evidence.

1. Learn how to evaluate the evidence behind the report

Read How to Evaluate Microbiome Tests, Probiotics, and Gut Health Claims. The Better Microbiome Thinking Framework introduces CLEAR, a practical method for examining the claim, scientific link, execution, agreement, and relevance of the evidence.

2. Examine a specific claim from your report

Paid subscribers can use the Claim Checker in the Resource Library to separate the measured result from the interpretation, recommendation, and commercial story attached to it.

3. Explain testing responsibly to patients or clients

The presentation How to Interpret Microbiome Test Reports Responsibly helps clinicians and nutrition professionals communicate what these tests measure, what remains uncertain, and how to avoid turning exploratory information into medical conclusions.

4. Request an independent scientific review

Companies, research teams, clinicians, and investors can visit Strategic Scientific Advisory for help evaluating microbiome tests, evidence, study designs, analytical claims, and clinical utility.

A microbiome report can provide observations and hypotheses. Its value depends on whether those observations are reliable, clinically meaningful, and capable of supporting a better decision.

The conclusion

Your microbiome report may contain real data. The central challenge is deciding where the data end and the story begins.

Diversity is a summary, not a diagnosis. Relative abundance is a proportion, not an absolute count. A beneficial bacterium is a context dependent research category, not a personal nutrient. A pathogen flag is a reason to confirm, not a reason to self treat. A pathway can describe capacity without proving activity. A percentile can rank you against a cohort whose relevance remains uncertain. A personalized recommendation can be general advice filtered through a proprietary score.

The microbiome is real. The certainty is often manufactured.

The useful response is better interpretation.

Define what was measured. Identify what was modeled. Ask whether the method is reproducible. Inspect the comparison group. Separate association from mechanism and mechanism from intervention. Match the confidence of your decision to the strength of the evidence.

That is how a microbiome report becomes information instead of instruction.

References

1. Qian XB and colleagues. A guide to human microbiome research. Chinese Medical Journal. 2020. DOI 10.1097/CM9.0000000000000871.

2. Knight R and colleagues. Best practices for analysing microbiomes. Nature Reviews Microbiology. 2018. DOI 10.1038/s41579-018-0029-9.

3. Franzosa EA and colleagues. Sequencing and beyond. Integrating molecular omics for microbial community profiling. Nature Reviews Microbiology. 2015. DOI 10.1038/nrmicro3451.

4. Cassol I and colleagues. Key features and guidelines for the application of microbial alpha diversity metrics. Scientific Reports. 2025. DOI 10.1038/s41598-024-77864-y.

5. Bindels LB and colleagues. A blueprint for contemporary studies of microbiomes. Microbiome. 2025. DOI 10.1186/s40168-025-02091-0.

6. Flores GE and colleagues. Temporal variability is a personalized feature of the human microbiome. Genome Biology. 2014. DOI 10.1186/s13059-014-0531-y.

7. Shade A. Diversity is the question, not the answer. The ISME Journal. 2017. DOI 10.1038/ismej.2016.118.

8. Gloor GB and colleagues. Microbiome datasets are compositional. And this is not optional. Frontiers in Microbiology. 2017. DOI 10.3389/fmicb.2017.02224.

9. Vandeputte D and colleagues. Quantitative microbiome profiling links gut community variation to microbial load. Nature. 2017. DOI 10.1038/nature24460.

10. Porcari S and colleagues. International consensus statement on microbiome testing in clinical practice. The Lancet Gastroenterology and Hepatology. Published online 2024. DOI 10.1016/S2468-1253(24)00311-X.

11. Depommier C and colleagues. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers. Nature Medicine. 2019. DOI 10.1038/s41591-019-0495-2.

12. McDonald LC and colleagues. Clinical practice guidelines for Clostridioides difficile infection. Clinical Infectious Diseases. 2018. DOI 10.1093/cid/cix1085. Johnson S and colleagues. 2021 focused treatment update. Clinical Infectious Diseases. 2021. DOI 10.1093/cid/ciab549.

13. Servetas SL and colleagues. Evaluating the analytical performance of direct to consumer gut microbiome testing services. Communications Biology. 2026. DOI 10.1038/s42003-025-09301-3.

14. Chey WD and colleagues. American College of Gastroenterology clinical guideline for treatment of Helicobacter pylori infection. American Journal of Gastroenterology. 2024. DOI 10.14309/ajg.0000000000002968.

15. Centers for Disease Control and Prevention. Diagnosis of parasitic diseases. 2024.

16. Douglas GM and colleagues. PICRUSt2 for prediction of metagenome functions. Nature Biotechnology. 2020. DOI 10.1038/s41587-020-0548-6.

17. Schirmer M and colleagues. Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. Nature Microbiology. 2018. DOI 10.1038/s41564-018-0262-y.

18. McDonald D and colleagues. American Gut. An open platform for citizen science microbiome research. mSystems. 2018. DOI 10.1128/mSystems.00031-18.

19. Vandeputte D and colleagues. Stool consistency is strongly associated with gut microbiota richness and composition. Gut. 2016. DOI 10.1136/gutjnl-2015-309618.

20. Anthony WE and colleagues. Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults. Cell Reports. 2022. DOI 10.1016/j.celrep.2022.110649.

21. Sinha R and colleagues. Assessment of variation in microbial community amplicon sequencing by the Microbiome Quality Control project consortium. Nature Biotechnology. 2017. DOI 10.1038/nbt.3981.

22. Costea PI and colleagues. Towards standards for human fecal sample processing in metagenomic studies. Nature Biotechnology. 2017. DOI 10.1038/nbt.3960.

23. Mirzayi C and colleagues. Reporting guidelines for human microbiome research. The STORMS checklist. Nature Medicine. 2021. DOI 10.1038/s41591-021-01552-x.

The Probiotic Decision Kit

The Probiotic Decision Kit helps dietitians, nutritionists, clinicians, and wellness professionals make more thoughtful probiotic recommendations. It provides a structured process for defining the client’s goal, evaluating strains and evidence, comparing products, and deciding whether a probiotic trial makes sense.

The kit includes decision tools, client conversation guides, case examples, worksheets, and the Try, Track, Stop framework for planning and evaluating a probiotic trial. It helps practitioners move beyond generic recommendations and create a clear process that can be explained, monitored, and documented.

Get the Probiotic Decision Kit here

How to Interpret Microbiome Test Reports Responsibly

This educational resource helps clinicians explain consumer microbiome testing clearly and responsibly. It covers what these tests measure, what the results may suggest, where uncertainty enters the process, and why a microbiome report should rarely be treated as a diagnosis or treatment plan.

The resource also gives clinicians practical language for discussing diversity scores, bacterial abundance, reference ranges, food recommendations, and changes between tests. Its purpose is to help clinicians answer patient questions without dismissing their interest or overstating what the science can currently support.

Microbiome Testing Guidance

guttitude

guttitude is a microbiome education and science intelligence platform created to help people understand gut health without getting lost in marketing claims or scientific jargon. It brings practical tools, evidence maps, product guidance, educational articles, and microbiome explainers together in one place.

Guttitude includes GutSense for tracking food, sleep, mindfulness, and broad microbiome support patterns. The Probiotic Decoder helps people compare probiotic strains, doses, formulations, study quality, and product claims. The Microbiome Signal Atlas connects microbes, metabolites, pathways, and health conditions through a structured evidence map. Additional resources help users examine popular gut health claims and understand what deserves attention before they spend money or change their care.

guttitude is designed for education and better decision making. It does not diagnose disease or directly measure an individual’s microbiome.

Try guttitude here

The Microbiome Network

Volume 1: Wired for Survival

How Trauma Rewires the Gut-Brain Axis

Wired for Survival unpacks the hidden biological cost of trauma through the lens of the gut-brain-immune connection. With a blend of science, lived experience, and clinical insight, this volume explains how chronic stress, early adversity, and unresolved emotional patterns reshape the microbiome—and how that shift influences inflammation, digestion, and mental health.

Drawing on research in neuroimmunology, psychobiotics, and epigenetics, the book explores:

• How trauma imprints itself into the immune system and gut lining

• The role of cortisol, cytokines, and gut bacteria in survival adaptation

• Why symptoms like IBS, brain fog, and fatigue are not “all in your head”

• What it means to have a trauma-adapted microbiome

• How to begin unwinding chronic dysregulation through breath, boundaries, and body awareness

Whether you’re a clinician treating stress-related illness or a survivor searching for answers, Wired for Survival offers a radically validating framework: your body isn’t broken. It’s protecting you. And with the right support, it can heal.

Get it here

Volume 2: Wired for Protection

The Immune System and Your Gut

In Wired for Protection microbiome researcher Dr. William DePaolo reveals the sophisticated electrical network running through your gut—a living circuit board where trillions of bacteria constantly communicate with 70% of your immune system. When this wiring functions properly, you feel energized, resilient, and protected. When it misfires, consequences show up everywhere such as, chronic fatigue, frequent infections, skin problems, autoimmune conditions, allergies, and even cancer risk.

This isn't just about digestion. This is about how your gut networks into every system you rely on to feel well and stay healthy.

Get it here

The beauty industry has discovered a remarkable business model.

Take a young science. Remove the uncertainty. Put it in a bottle. Call it balance.

I have worked in microbiome science for more than fifteen years. I believe microbial therapies may eventually become genuinely useful. I also know how enormous the distance can be between changing a microbial measurement and improving human health.

Microbiome skin care lives inside that distance.

Brands tell consumers that their skin ecosystems need to be balanced, nourished, protected, restored, and occasionally rescued by an expensive serum. The language sounds scientific. The evidence behind it is often vague, preliminary, borrowed from an unrelated product, or missing entirely.

The skin microbiome is real.

The restoration story being sold around it is far more certain than the science.

That gap is where the bullshit begins.

The probiotic that contains no probiotic

A probiotic is a live microorganism administered in an adequate amount that produces a demonstrated health benefit. The words live, adequate, and demonstrated all matter.

A bacterial name printed on a package cannot satisfy that definition by itself. The strain must be identified, remain viable through the end of the product’s usable life, reach the target site at an effective dose, and produce a benefit in an appropriate human study. Those requirements come from the widely used scientific consensus definition of probiotics.

Many products sold as probiotic skin care contain ferments, filtrates, or lysates instead. These materials can have biological activity, though they are different interventions.

A postbiotic is a preparation containing inanimate microorganisms or their components that confers a health benefit. The consensus definition requires the progenitor organisms to be characterized and the benefit to be demonstrated. Purified metabolites and filtrates without microbial cell components fall outside that definition, according to the International Scientific Association for Probiotics and Prebiotics consensus statement.

This creates an awkward reality for cosmetic marketing. A ferment is not automatically a postbiotic. A dead bacterium is not automatically beneficial. A lysate is not a probiotic. Each term describes a type of material. None serves as evidence that the finished product works.

One preprint describing a market analysis estimated that at least 84 percent of commercial topical products marketed with probiotic language lacked live microorganisms. The figure is a warning signal rather than a settled statistic.

The exact percentage matters less than the labeling problem. Consumers are routinely invited to believe that microbial fragments and fermentation ingredients are living organisms capable of colonizing the skin.

Cosmetics are designed to control microbial growth

A water containing cream sitting in a warm bathroom is a welcoming environment for contamination. Manufacturers use preservation systems to prevent bacteria and fungi from growing inside the package. The United States Food and Drug Administration identifies ineffective preservation as a contamination risk and makes manufacturers responsible for cosmetic safety. See the FDA discussion of microbiological safety.

These requirements create a basic formulation conflict. The product must suppress microbial growth inside the package while supposedly keeping selected microorganisms alive.

Common cosmetic preservatives inhibited cultured bacteria isolated from healthy facial skin, although susceptibility varied by organism and preservative. This shows why viability must be measured in the finished formulation throughout storage rather than assumed from an ingredient list. See the study of preservatives and facial skin bacteria /).

Live topical formulations remain possible through dry powders, microcapsules, oil based systems, refrigeration, and mixing immediately before application. Those solutions reveal how different a serious microbial intervention is from an ordinary moisturizer carrying probiotic language.

If a company claims to sell live probiotics, it should disclose the strain, viable count at the end of shelf life, storage conditions, dose delivered to the skin, and evidence from the finished formulation.

Without those data, probiotic is decoration.

A percentage measured in a plate becomes a promise about human skin

Microbiome studies can show that a product changed the relative abundance of a bacterium. That finding is frequently treated as evidence that the product restored balance.

Balance is rarely defined.

Skin communities vary by body site, physiology, environment, and individual. The two year facial microbiome study found broad stability alongside substantial changes in some individuals. This makes a universal microbial target difficult to justify.

Inflammation, altered lipids, barrier damage, medications, and scratching can all change the microbial habitat. A microbe can be a cause, consequence, contributor, passenger, or several of these at once. Observing more of an organism in healthy skin does not establish that adding it will restore health. Even a meaningful reduction in Staphylococcus aureus remains distinct from preventing infection or reducing disease over months.

This same category error appears in dramatic laboratory results.

One study tested a cosmetic gel containing bacteriophages and Aloe vera against bacterial isolates. The formulation produced a 97.11% reduction in S. aureus cell viability in a laboratory assay.

That number sounds almost curative when removed from context.

The experiment did not apply the product to people or demonstrate fewer infections or treatment failures. It established laboratory activity and formulation feasibility. It provided no clinical efficacy estimate. The distinction is visible in the phage formulation study .

Microbiome science requires clinical endpoints. Cosmetic marketing often settles for microbial movement.

The promising studies are real

There are legitimate signals in the literature.

A carefully formulated cream containing three live lactobacilli strains was evaluated in people with mild to moderate acne. Sixty seven participants completed the placebo controlled study. After four weeks, inflammatory lesions declined by 34.4% in the treatment group and 1.7% with placebo. Some lesion improvement remained after treatment ended, according to the published acne study.

That result supports further development of that particular formulation for that particular population. It does not validate unrelated creams containing an unspecified Lactobacillus ferment.

Atopic dermatitis has produced several encouraging experiments involving antimicrobial producing staphylococci, Staphylococcus hominis A9, and Roseomonas mucosa. Sample sizes ranged from eleven participants in a personalized bacteriotherapy trial]to 54 in a phase one ShA9 trial. The early [Roseomonas studyincluded only fifteen people and lacked a placebo group.

These results establish plausibility and support further research. They cannot carry the evidentiary weight placed on them by an entire cosmetic category.

The strongest evidence may come from B244, a live ammonia oxidizing bacterium evaluated in 547 adults with atopic dermatitis and substantial itch. In a randomized phase two trial, itch scores improved by 2.8 points with B244 and 2.1 points with vehicle. The difference was statistically significant. The developer funded the study and several investigators had company affiliations. Even with that caveat, the B244 phase two trial provides meaningful support for continued drug development.

These interventions resemble experimental medicines. They use defined organisms, controlled manufacturing, measured doses, enrolled disease populations, and prespecified clinical outcomes.

Their existence shows that microbial therapy can be credible.

Their complexity exposes how little evidence supports most retail products.

Postbiotics deserve evidence too

Postbiotics are attractive because they cannot replicate and generally tolerate manufacturing and storage better than live microorganisms. Their components may interact with immune receptors, barrier pathways, or resident microbes.

Greater stability solves a formulation problem. It does not establish efficacy.

One frequently cited EPI 7 clinical study enrolled 55 healthy Korean women, with 52 completing a three week split face comparison. The ferment filtrate side had a 12.5% reduction in transepidermal water loss compared with 1.7% for the vehicle side.

The short duration, narrow population, surrogate endpoints, undisclosed portions of the active preparation, and lack of independent replication make the result preliminary. The published information also leaves unclear whether the preparation contained the microbial cell components required under the consensus postbiotic definition.

A product may improve hydration or water loss without restoring a microbial ecosystem. A conventional moisturizer can do both. Researchers need to show whether the microbial ingredient contributes beyond the vehicle and whether any microbiome change mediates the clinical outcome.

Artificial intelligence cannot rescue uncertain biology

The individuality of the skin microbiome is often used to predict personalized products designed by artificial intelligence. Evidence for current commercial usefulness remains thin.

Personalization becomes valuable when a validated measurement identifies which intervention will produce a better outcome for a particular person. That requires a reproducible test, a clinically relevant classification, and prospective evidence. A microbial skin cluster generated by an algorithm is only a description until acting on it improves outcomes.

Artificial intelligence can automate the production of confident recommendations from uncertain biology. It cannot give an undefined endpoint clinical meaning.

The regulatory gap rewards ambiguity

Cosmetics in the United States generally enter the market without prior FDA approval. Their labels must be truthful and their products must be safe. Claims that a product treats disease or affects the structure or function of the body can cause it to be regulated as a drug. The FDA explains this boundary in its cosmetic labeling guidance.

Terms such as microbiome friendly, balancing, harmonious, and supportive thrive near this boundary. They sound biological while avoiding a clearly testable therapeutic promise.

A genuine live biotherapeutic intended to treat disease enters a far more demanding world involving strain identity, purity, potency, manufacturing controls, stability, and clinical investigation. The FDA guidance for live biotherapeutic trials makes that complexity clear.

The regulatory gap is part of the business model. Cosmetic language captures the excitement of microbial therapeutics while avoiding much of the evidentiary burden attached to them.

What credible evidence would look like

A credible product would identify every strain and disclose what is present in the finished formula. A live product would report viable counts through the end of shelf life, storage conditions, delivered dose, and contamination controls. A postbiotic would describe the progenitor strain, manufacturing process, inactivation method, relevant components, and dose.

The finished product would be tested against an appropriate vehicle in an adequately powered human trial. The primary outcome would be selected in advance and matter to the user. Follow up would show whether the benefit persists. The analysis would separate clinical improvement from microbial association.

Scientific names on an ingredient list are insufficient. Certifications can assess selected manufacturing or microbiome compatibility criteria, though they do not substitute for product specific clinical efficacy.

The verdict

Microbiome skin care is a scientific idea surrounded by commercial theater.

Defined live bacterial therapies have produced encouraging clinical signals in acne and atopic dermatitis. Specific inanimate microbial preparations may improve barrier measurements or other skin outcomes. These findings justify rigorous development.

They do not justify the broad claim that a conventional cosmetic containing a ferment or lysate balances, restores, or repairs an individual microbial ecosystem.

The industry has taken a young field filled with unresolved questions and marketed the resolution. It sells ecological precision without an agreed definition of a healthy ecosystem. It sells probiotics that frequently contain no live organisms. It cites therapeutic trials involving defined strains and controlled manufacturing to lend credibility to unrelated consumer formulas. It converts microbial changes into health claims and laboratory percentages into implied clinical outcomes.

The science may eventually produce valuable therapies.

The bottle on the shelf still has to prove that it is one of them.

The microbiome field has developed a convenient explanation for almost every inconsistent result. The biology is complicated.

That explanation is often correct. Microbiomes vary across people, anatomical sites, geography, medications, diet, disease state, collection time, and countless other exposures. But biological complexity has also become a remarkably effective shield against examining a more controllable source of variability such as how the research was actually conducted.

When studies disagree, investigators often reach first for ecological explanations. They invoke interpersonal variation, strain-level differences, temporal instability, population heterogeneity, or unmeasured confounders. Those possibilities deserve consideration. So do extraction efficiency, sample preservation, freeze-thaw history, reagent lots, plate layout, technician performance, sequencing batches, protocol deviations, and incomplete metadata.

The field cannot keep treating every unexplained difference as an interesting feature of microbial ecology. Sometimes the biology is complicated. Sometimes the operation is poorly controlled.

We already know laboratory decisions can change the answer

The evidence has been sitting in the literature for years.

The Microbiome Quality Control project distributed standardized samples to multiple laboratories and found substantial variation in the resulting taxonomic profiles. The effects were not limited to which bioinformatics software was used. Laboratory and protocol choices influenced the organisms detected and their estimated relative abundances. The project explicitly recommended standardized samples, positive controls, negative controls, and detailed protocol documentation as part of microbiome quality assurance. The original MBQC study established the multicenter framework, and its subsequent analysis demonstrated substantial protocol-associated variability in taxonomic profiling. MBQC variability assessment

In another major comparison, Costea and colleagues tested 21 DNA extraction protocols on the same fecal specimens. DNA extraction produced the largest technical effect on metagenomic results, including differences in measured diversity and the apparent balance between Gram-positive and Gram-negative organisms. The investigators did not merely call for researchers to acknowledge this limitation. They evaluated protocol performance, tested transferability between laboratories, benchmarked the workflow with a mock community, and recommended a standardized extraction procedure. Nature Biotechnology study

The operational lesson is larger than “extraction kits matter.” A laboratory method should be qualified against known materials before it is used to generate hundreds or thousands of study results. Its bias should be characterized, its performance boundaries should be understood, and its reproducibility should be demonstrated across operators, days, reagent lots, and instruments.

Preanalytical variation is part of the experiment

The experimental workflow begins when a participant receives a collection kit, not when DNA enters a sequencer.

Preservation conditions, transport time, temperature exposure, homogenization, aliquoting, storage duration, and freeze-thaw cycles can all affect the material eventually measured. The magnitude of each effect depends on the analyte and assay. DNA-based taxonomy, RNA, metabolites, proteins, viable organisms, and absolute microbial load do not respond identically to collection and storage conditions.

A 2022 study that deliberately introduced technical variation into fecal metagenomic workflows identified storage conditions and freeze-thaw cycles as major sources of unwanted variation. The authors also showed that technical effects could interfere with genuine biological signals. Scientific Reports study More recent work examining stool collection for multi-omic analysis found that preservation buffer meaningfully affected the observed microbial composition. Stool preservation study

That doesn’t mean every sample has to be processed immediately or that there’s one universally correct preservation method. The right collection approach depends on what you plan to measure. A method that works well for DNA profiling may perform poorly when the goal is to analyze RNA, metabolites, live organisms, or microbial function.

Research programs should define acceptable transport windows, temperature ranges, storage conditions, and freeze-thaw limits before enrollment begins. Excursions should be documented at the specimen level. A sample that spent two days in an uncontrolled mailbox should not silently become analytically equivalent to one frozen immediately at collection.

Batch effects should be designed out, not merely corrected later

Batch effects are especially dangerous when technical variables align with the biological comparison.

If cases are extracted on one set of plates and controls on another, disease status becomes inseparable from extraction batch. If baseline samples are processed with one reagent lot and follow-up samples with another, longitudinal change becomes entangled with laboratory change. No elegant statistical method can reliably reconstruct information that the study design made impossible to separate.

Published work has shown that batch effects can create false-positive associations, hide genuine associations, and compromise biomarker and prediction models. Statistical tools can reduce some unwanted variation, but they cannot guarantee that biological signal and technical bias have been correctly identified. Nature Communications batch-effect analysis

The operational solution is prospective batch architecture. Study groups should be balanced across extraction plates, library preparations, sequencing runs, operators, and relevant reagent lots whenever possible. Longitudinal specimens from the same participant should be handled according to a predefined batching strategy. Replicate samples and reference materials should bridge batches so that drift can be measured rather than guessed at afterward.

Controls must diagnose the workflow

Many microbiome studies include controls because reviewers expect them. Fewer build a control system capable of locating failure.

An extraction blank can identify contamination introduced during nucleic acid isolation. A library blank can help localize contamination introduced later. A whole-cell mock community can test lysis, extraction, library preparation, sequencing, and analysis together. A DNA mock community bypasses lysis and therefore tests a different portion of the workflow. Replicates can estimate precision, while a stable reference material analyzed across runs can reveal drift.

These materials are not interchangeable. Including “a negative control” without defining what it controls, when it enters the workflow, and what result would trigger investigation is quality theater.

Reviews of microbiome control practices have found inconsistent use and reporting of negative controls, positive controls, and mock communities. They also emphasize that low-biomass studies are particularly vulnerable because contaminating DNA can constitute a substantial proportion of the recovered signal. Review of microbiome controls. Well-characterized whole-cell and DNA mock communities are now available specifically to support performance assessment across different stages of gut microbiome measurement. Mock-community characterization study

A serious microbiome operation should establish acceptance criteria before samples are processed. Those criteria might include extraction yield, library yield, sequencing depth, contamination thresholds, expected recovery of reference organisms, replicate concordance, and predefined rules for failure, repeat testing, or exclusion. A control that cannot cause a run to fail is mostly decoration.

Metadata are operational data

The microbiome field speaks constantly about metadata, but metadata quality is often treated as a participant-compliance problem or a database problem. It is an operational design problem.

Medication exposure cannot be analyzed consistently if one study coordinator records “antibiotics: no,” another records a drug name without dates, and another leaves the field blank. Collection time cannot be evaluated if the database stores the time a package was received instead of the time the specimen was produced. A freezer location is not reliable because it exists in a spreadsheet. It is reliable when specimen movements are controlled, recorded, reconciled, and auditable.

The STORMS reporting guidelines provide an important checklist for describing human microbiome studies, including sample collection, laboratory processing, bioinformatics, statistical analysis, and relevant exposures. But reporting standards solve only part of the problem. Accurately reporting an uncontrolled process does not make that process controlled.

Programs need data dictionaries, required fields, standardized exposure windows, controlled terminology, timestamp definitions, missing-data rules, and responsibility for resolving discrepancies. They also need to connect clinical metadata with specimen-level operational information, including processing dates, operators, plates, instruments, reagent lots, deviations, and freeze-thaw history.

Without that linkage, investigators can detect a batch effect but may be unable to determine what caused it.

SOPs are not enough

A laboratory can have a beautifully formatted standard operating procedure and still run an inconsistent process.

An SOP describes the intended workflow. It does not prove that the workflow performs adequately, that staff execute it consistently, or that undocumented adaptations have not accumulated over time. In many research laboratories, the real method is distributed across the SOP, handwritten notes, old emails, instrument settings, and the memory of the most experienced research associate.

Each critical workflow should have an owner, a controlled procedure, documented training, competency assessment, version history, defined materials and equipment, acceptance criteria, and a deviation process. When the workflow changes, the team should evaluate whether the change could affect prior and future data. Significant changes may require bridging studies before results generated under the two methods are combined.

Troubleshooting should also become structured. Recurring failures, contamination events, yield problems, and control excursions should be logged and analyzed for patterns. Corrective actions should identify causes and prevent recurrence instead of ending with “repeat the extraction.”

If a platform depends on one senior employee knowing how to rescue it, the organization has not built a robust platform. It has built a shrine to one person’s memory.

What stronger microbiome research operations look like

Microbiome programs do not need to turn every exploratory project into a regulated clinical laboratory. They do need a level of control proportional to the claims being made.

An exploratory pilot identifying potential signals may tolerate more uncertainty than a multicenter clinical study. A commercial assay, longitudinal intervention trial, or biomarker-development program requires considerably stronger control. Operational rigor should scale with the consequence of being wrong.

A credible program should be able to demonstrate six things:

1. The intended use is defined. The organization knows what biological question the assay is meant to answer and what level of performance that answer requires.

2. The specimen lifecycle is controlled. Collection, transport, receipt, accessioning, storage, aliquoting, processing, and disposal are defined and traceable.

3. The workflow is qualified. Precision, bias, contamination risk, robustness, and relevant limits have been evaluated using reference materials, replicates, and deliberate perturbations.

4. Technical variation is separated from biological comparison. Samples are randomized or balanced across operational variables, and bridging controls connect batches over time.

5. Performance is monitored continuously. Controls have acceptance criteria, deviations trigger investigation, and longitudinal metrics reveal drift before it contaminates an entire study.

6. Every result is reconstructable. The organization can connect a reported finding to the raw data, pipeline version, reference database, specimen history, reagent lots, instrument run, operator, and protocol version that produced it.

This is not bureaucracy layered onto science. It is how an organization establishes whether its measurement system is capable of supporting its scientific claims.

Operations determine what can be learned

The microbiome field keeps asking for larger cohorts, deeper sequencing, more advanced multi-omics, and increasingly elaborate machine-learning models. Those investments can improve the science. They can also amplify operational weaknesses.

More samples do not rescue a systematically biased workflow. Deeper sequencing does not correct poor preservation. Artificial intelligence cannot recover metadata that were never collected. A sophisticated analysis pipeline cannot separate disease status from batch when every case and every control were processed differently.

Microbiome biology is genuinely complex. That is precisely why the operational system surrounding it must be unusually disciplined. When the biological signal is variable, multidimensional, and context dependent, researchers have less room for preventable technical noise, not more.

The next generation of strong microbiome programs will not distinguish themselves solely through sequencing technology or computational sophistication. They will distinguish themselves by controlling the complete system that turns a biological specimen into a scientific claim.

Before explaining away an inconsistent result as microbial complexity, investigators should be able to show what happened to every sample, how the workflow performed, what the controls detected, what changed between batches, and whether another trained team could reproduce the measurement.

If they cannot do that, they do not yet know whether they are studying biology or documenting the behavior of their own laboratory.

That is not merely a reproducibility problem. It is a research operations failure.

Need Stronger Microbiome Research Operations?

I help microbiome companies, research programs, and clinical teams build the operational systems required to produce credible, reproducible results.

I bring more than 20 years of experience across microbiome science, immunology, translational research, laboratory leadership, clinical studies, and biotechnology operations. I have founded and directed an academic microbiome center, led multidisciplinary research programs, overseen human microbiome studies, developed laboratory and analytical workflows, managed clinical trials, and helped organizations translate complex science into executable research programs.

FOr more information Click Here

Subscribe now

Seven microbiome testing companies received material from the same standardized stool sample, and they did not return the same microbiome. That finding should have triggered a much larger reckoning across the direct-to-consumer testing industry. Instead, it was treated as another technical study, briefly discussed and then largely absorbed without consequence.

In my previous article, I focused on the decision to keep the companies anonymous. Seven commercial microbiome testing services were evaluated, substantial discrepancies were found, and the public was denied the information needed to distinguish stronger performers from weaker ones. That remains unacceptable. But anonymity is only the first problem exposed by the study. The deeper issue is what the disagreement says about the product itself.

These companies are not simply producing slightly different descriptions of the same biological reality. Their methods may be producing meaningfully different versions of that reality. That raises a question the industry has avoided for too long. What, exactly, is the consumer paying to have measured?

Same Stool, Different Microbiomes

The National Institute of Standards and Technology study evaluated seven direct-to-consumer gut microbiome testing services using standardized human fecal material. Researchers found major discrepancies both between companies and within individual companies. The variability between providers was reportedly comparable in scale to the biological variability observed between different donors.

That is not a small technical disagreement. It cuts directly into the meaning of the test. If the difference between two companies analyzing the same material can resemble the difference between two different people, then the consumer is not receiving a straightforward description of what is present. The result is being heavily shaped by the testing company itself.

NIST later explained the experiment in more accessible terms. Researchers sent identical stool material from one donor to seven companies without telling them they were participating in a study. The reports differed substantially. One company classified the sample as representing an unhealthy gut microbiome, while the others did not.

The sample did not become unhealthy inside one shipping box and recover inside the other six. The companies saw different microbiomes because they used different approaches to collection, preservation, processing, sequencing, identification, calculation, comparison, and interpretation. Those choices are not minor details surrounding the product. They are the product.

Your Report May Be Measuring the Company as Much as It Measures You

Consumers are encouraged to think of microbiome testing as simple observation. You send in your stool, the company examines it, and the company tells you what is there. That description makes the process sound almost passive, as though the microbiome already exists as a clean list of organisms and percentages that only needs to be revealed.

It does not work that way. A stool sample contains an extraordinarily complex mixture of microbial cells, human cells, food material, metabolites, free DNA, dead organisms, and other biological debris. Turning that mixture into a consumer report requires a long chain of technical and interpretive decisions.

The company must decide how the sample will be collected and preserved, how DNA or RNA will be extracted, which sequencing method will be used, which controls and thresholds will be applied, which database will assign microbial identities, and how ambiguous sequences will be handled. It must also decide how relative abundance will be calculated, which organisms will be excluded, which population will define normality, and how the resulting data will be converted into scores, warnings, food recommendations, or health interpretations.

Every one of those decisions can change the result. The final report is therefore not simply a portrait of the consumer’s microbiome. It is a portrait produced through one company’s laboratory methods, software, reference databases, assumptions, thresholds, and commercial philosophy.

Send the same sample to another provider and you may receive another portrait. The consumer remains the same. The interpretive machinery changes.

Precision Formatting Is Not Measurement Accuracy

Microbiome reports often look remarkably precise. A bacterium may be reported as 2.74 percent of the community. Diversity may be reduced to a score out of 100. Organisms may be ranked, flagged, color-coded, and displayed inside polished dashboards. Foods and supplements may be recommended with reassuring specificity.

The interface creates a powerful psychological effect. Numbers with decimal places look measured. Scores look standardized. Green and red indicators look clinically meaningful. Personalized recommendations look like the logical endpoint of an objective process.

But precision in presentation does not prove accuracy in measurement. A company can report the wrong answer to two decimal places. A dashboard can be beautifully designed and scientifically unstable at the same time. In fact, polished design can make the instability harder to see because uncertainty has been converted into visual confidence.

The NIST findings expose the danger of mistaking numerical detail for analytical truth. Before a company tells someone that a bacterium is high, low, beneficial, concerning, or associated with a health condition, it should first show that it can reliably detect and quantify that organism. Before it assigns a microbiome score, it should show that the underlying measurements are reproducible. Before it recommends changing a diet or buying a supplement, it should show that the analytical result is dependable enough to support the interpretation.

The correct order is obvious. Measurement first. Interpretation second. Recommendation last. Much of the industry has developed those layers in reverse. The consumer-facing interpretation is highly polished, while the scientific foundation beneath it remains difficult to inspect.

Internal Inconsistency Is Even Harder to Excuse

Disagreement between companies is concerning, but some of it can at least be explained. Different providers may use different technologies and measure different biological features. One may detect DNA while another examines RNA. One may use targeted sequencing while another uses whole metagenomic sequencing.

Those distinctions matter, and they should be disclosed prominently because consumers cannot reasonably compare results generated by fundamentally different systems. A 16S-based report is not interchangeable with a shotgun metagenomic report, and neither is automatically equivalent to a metatranscriptomic analysis.

The more serious problem is that the NIST work also found inconsistency within individual companies. Researchers submitted multiple samples drawn from the same composite fecal material to each service. The results suggested that some providers were not consistently reproducing their own findings.

That is a more basic failure. A company should be able to analyze equivalent samples and return reasonably equivalent results. Perfect replication is unrealistic in any biological assay, but the expected range of variation should be characterized, controlled, and disclosed.

Consumers should not have to wonder whether a bacterium appeared because it was meaningfully present or because the pipeline happened to detect it that day. They should not have to wonder whether an unhealthy designation reflects their biology or the reproducibility limits of the assay. They should not be asked to pay for repeated testing to track change until the company has demonstrated that the test can distinguish true biological change from its own analytical noise.

Without that evidence, longitudinal testing risks becoming theater. The report changes, so the consumer assumes the microbiome changed. But some portion of that movement may belong to the test itself.

Complexity Is Not an Excuse

The microbiome field has become very good at explaining why its measurements disagree. Different extraction kits recover different organisms. Different primers amplify different sequences. Different preservation methods alter what survives. Different platforms produce different read profiles. Different databases assign different names. Different pipelines apply different thresholds, filters, and statistical choices.

All of that is true. None of it excuses the result.

These technical differences are often treated as though they absolve the companies involved. They do the opposite. They show that the industry has commercialized a measurement before agreeing on how that measurement should be produced, compared, and interpreted.

Complexity has become a convenient hiding place. When results conflict, the explanation is always another layer of methodology. Different kit. Different machine. Different database. Different algorithm. Different reference population. The list can continue indefinitely, and every additional variable makes responsibility easier to dissolve.

But consumers are not purchasing extraction kits, sequencing platforms, or bioinformatics pipelines. They are purchasing an answer about their microbiome. If the answer changes dramatically depending on which technical pathway produced it, then the company must either prove that its pathway is valid or stop presenting the output as an authoritative description of the consumer.

The existence of confounders does not reduce the obligation to validate a test. It increases it.

A company cannot claim that its pipeline is sophisticated when marketing the product, then claim that microbiome science is too complicated when the product fails to agree with competitors or reproduce itself. It cannot use complexity as proof of innovation on the sales page and as an excuse for inconsistency when challenged.

When the result supports the company’s recommendation, the interpretation is presented with confidence. When the result is questioned, the field suddenly becomes impossibly complicated. The biology is treated as knowable when there is something to sell and unknowable when there is something to defend.

That double standard has allowed the industry to move forward without resolving basic measurement problems. The field has normalized disagreement so thoroughly that it now treats inconsistency as an interesting technical feature rather than a threat to the validity of the product.

It should be the opposite. The more variables a method contains, the stronger the validation should be. The more pipelines differ, the more urgently companies should participate in blinded comparisons, standardized testing, and public performance reporting.

Complexity does not make accountability impossible. It makes accountability necessary.

Personalization Built on Unstable Measurement Is Not Personalization

Microbiome companies frequently sell personalization. They offer personalized food recommendations, personalized probiotics, personalized supplements, and personalized wellness plans. But personalization does not become scientifically meaningful merely because an algorithm uses individual data.

The data must first be dependable. An unreliable measurement passed through a personalized algorithm does not become more reliable. It becomes unreliable advice with the consumer’s name attached.

That distinction matters because microbiome recommendations can change real behavior. People may remove foods, add supplements, repeat expensive tests, or become anxious about organisms they had never heard of before receiving the report. Some consumers approach these services out of curiosity. Others are dealing with chronic gastrointestinal symptoms, inflammatory conditions, fatigue, or unresolved health concerns.

Those consumers may be especially susceptible to a report that appears to explain why they feel unwell. A disclaimer stating that the test is not diagnostic does not erase the effect of a report that labels findings as undesirable, unbalanced, inflammatory, dysbiotic, or unhealthy. The language may stop just short of diagnosis while still leading the consumer directly toward a medical interpretation.

That is not a harmless semantic trick. It is a way of claiming scientific authority while trying to avoid the obligations that should come with it.

There Is Still No Universally Accepted Healthy Microbiome

Even if every company measured the sample perfectly, another problem would remain. What does a healthy gut microbiome actually look like?

There is no single, universally accepted microbial composition that defines health across populations, diets, ages, geographies, medications, lifestyles, and medical histories. Microbiome research has identified associations between certain community features and particular diseases, but association does not automatically establish cause, diagnostic value, or an appropriate intervention.

A bacterium associated with disease may contribute to that disease, expand because the intestinal environment has changed, or simply coexist with the process. The direction and importance of the relationship can vary by organism, strain, ecological context, and host.

Consumer reports often compress this uncertainty into simple categories such as good, bad, high, low, balanced, unbalanced, healthy, or unhealthy. That simplicity is commercially useful because it gives the consumer a clear answer. It is also scientifically misleading when the categories exceed what the evidence can support.

A microbiome score is especially seductive because it suggests that health can be ranked along a single axis. But a complex ecosystem cannot be reduced to one number without making a large number of hidden value judgments. The company must decide which organisms count, how they are weighted, which population serves as the reference, and which outcomes define success.

The crucial questions are rarely visible to the buyer. Does a higher score predict anything clinically meaningful? Can the score distinguish healthy people from sick people? Does changing the score improve health? Was it validated across populations, or only within one narrow dataset?

Until those questions have been answered, the number may function more as product design than health measurement.

The Industry Cannot Solve This With Better Disclaimers

Companies often respond to criticism by emphasizing that their products are educational or intended for general wellness. That defense is inadequate.

A company cannot wrap a health interpretation in wellness language and pretend that the scientific obligations disappear. When a report evaluates the consumer’s gut, categorizes microbial findings, compares them with a reference population, and recommends actions intended to improve health, the quality of the underlying measurement matters.

Calling the report educational does not make a false finding more educational. Calling a recommendation general wellness does not make it evidence-based. Calling a score proprietary does not exempt it from validation.

The relevant question is not what regulatory category the company would prefer the product to occupy. The relevant question is how consumers are likely to understand and use the information.

If a company wants the authority that comes with individualized biological testing, it must accept the burden of demonstrating that the test performs reliably.

What Companies Should Be Required to Show

The solution is not to ban consumer access to microbiome information. The solution is to stop allowing companies to substitute confidence for evidence.

Every direct-to-consumer microbiome testing company should publicly report its analytical method, sample collection and preservation procedures, within-run and between-run reproducibility, performance using standardized reference materials, detection limits, known taxonomic biases, and contamination controls. It should also disclose the reference databases it uses, how those databases are updated, and what happens when changes to the pipeline alter previous interpretations.

Companies should explain which populations were used to define normality, balance, or health. They should show the validation evidence behind every score and recommendation. They should also tell consumers how much variation to expect when the same sample is tested repeatedly.

Independent proficiency testing should become routine. Companies should receive blinded standardized materials and be evaluated on whether they can reliably measure what they claim to measure. The goal would not be to force every provider to use the same technology or produce identical reports. Different methods can answer different questions.

The goal would be to determine whether each company can perform its chosen method reliably, explain its limitations honestly, and avoid making claims that exceed the evidence.

NIST has already developed human stool reference material intended to improve comparability and reproducibility in microbiome measurement. The technical path forward is not mysterious. What is missing is the pressure to make companies use it.

The Burden of Proof Belongs to the Seller

Consumers should not have to become sequencing experts to determine whether a microbiome test is credible. They should not have to understand extraction bias, compositional data, reference database limitations, strain-level resolution, batch effects, or algorithm versioning before purchasing a test marketed as an accessible window into their health.

That responsibility belongs to the company selling the window.

If a business claims it can measure the microbiome, it should prove that it can measure the microbiome. If it assigns health meaning to the result, it should validate that meaning. If it recommends an action, it should show that the recommendation follows from reliable evidence.

When a company cannot do those things, it should narrow its claims until they match what has actually been demonstrated. That is not hostility toward innovation. It is the minimum price of credibility.

What Are These Companies Actually Selling?

The NIST study did more than reveal variation among seven testing services. It exposed an identity crisis inside the direct-to-consumer microbiome industry.

Are these companies selling laboratory measurements, research participation, educational reports, wellness coaching, dietary recommendations, health-risk interpretations, or subscription-based biological tracking? The answer often changes depending on the audience.

The test is presented as scientifically advanced when being sold, personalized when being interpreted, educational when being challenged, and nonmedical when regulation is discussed. That flexibility is commercially convenient. It is not an acceptable substitute for defining the product and validating its performance.

A company should not be allowed to borrow the visual language of diagnostics, the authority of biomedical science, and the intimacy of personalized medicine while retreating into general wellness whenever someone asks whether the result is accurate.

Seven companies were given the same biological material and returned different answers. The industry can spend another decade explaining why. It can point to extraction chemistry, sequencing technology, database architecture, computational thresholds, and the untamed complexity of microbial ecology.

But at some point, explanation becomes avoidance.

These companies chose to commercialize the tests. They chose to convert uncertain measurements into scores, rankings, health labels, and recommendations. They chose to present those outputs as personalized insight. They do not get to retreat behind methodological complexity when the results fail to agree.

If the methods are too variable to produce dependable answers, then the tests are not ready to support the claims being made. If the companies believe their own methods are superior, they should prove it publicly. If they cannot, they should stop selling uncertainty in the visual language of precision.

The microbiome may be complex. The obligation is not.

Prove the test works, disclose where it does not, and stop pretending that another pipeline explanation settles the matter.

Janeen Interlandi’s July 8th 2026 New York Times Magazine article "Our Bacteria Are Talking. We've Just Begun to Understand What They're Saying" is a serious and valuable piece of microbiome journalism. It exposes one of the field’s most consequential failures. We have tried to define the human microbiome using samples drawn disproportionately from wealthy, industrialized, geographically narrow populations, then treated the patterns found in those cohorts as though they represented humanity.

They do not.

A model that can distinguish health from disease in the United States, Canada, or Western Europe but fails when applied elsewhere has not discovered a universal microbial signature of health. It has discovered the limits of its reference population. That failure could reflect real biological differences, but it could also reflect diet, medication exposure, social conditions, disease prevalence, sample handling, database bias, technical variation, overfitting, or some combination of all of them.

The Global Microbiome Conservancy is trying to correct part of this problem by collecting, culturing, sequencing, and preserving organisms from populations that microbiome science has largely ignored. That work is important. It expands the range of human-associated microbial diversity available for study, improves reference databases, creates access to viable strains, and gives researchers the ability to ask questions that would otherwise become impossible if those organisms disappear.

But the project does not solve the central problems of microbiome science.

It expands the map. It does not tell us what health is.

It preserves organisms. It does not establish their causal importance.

It creates a global collection. It does not automatically create global equity.

It generates biological possibility. It does not guarantee clinical utility.

Those distinctions matter because microbiome science has a habit of moving quickly from observation to meaning. We detect a difference and call it dysbiosis. We find lower diversity and call it depletion. We identify an organism in a healthy population and call it beneficial. We recover a strain absent from industrialized cohorts and begin imagining restoration.

The collection is real. The meaning is still under investigation.

Expanding the Map Does Not Define Health

The Conservancy addresses a genuine reference problem. Most microbiome datasets are not representative of the world’s populations, diets, environments, social structures, or medical exposures. Broadening that reference universe is scientifically necessary.

But a larger and more diverse collection will not produce a universal healthy microbiome simply by adding more samples.

The idea of a healthy microbiome is already unstable. Health is not one taxonomic state. Two healthy people can have substantially different microbial communities. Different populations may maintain similar biological functions through different organisms. A community that looks depleted relative to one reference group may be normal within another ecological and cultural context.

This is why diversity is such a dangerous shortcut. Higher microbial diversity is often treated as inherently healthier, even though that relationship is not universal. Infant microbiomes are naturally less diverse than adult microbiomes. Vaginal communities dominated by specific Lactobacillus species may be low in diversity and protective. Increased diversity can sometimes reflect instability, invasion, or the mixing of ecological niches.

More organisms do not automatically mean better function. Fewer organisms do not automatically mean disease.

A global collection can show us how much microbial variation exists. It can reveal which taxa and genes are common, rare, geographically restricted, or associated with particular lifestyles. It cannot determine health without longitudinal data, host physiology, clinical outcomes, diet, medication history, microbial activity, and ecological context.

The map gets larger. The definition of health may become more complicated, not less.

That would still be progress.

Preserving an Organism Does Not Establish Its Importance

The Conservancy’s decision to culture strains rather than merely sequence stool samples is one of its greatest scientific strengths. Sequencing tells researchers that genetic material was detected. Culturing produces viable organisms that can be studied, manipulated, combined into defined communities, and tested experimentally.

But culturing also introduces another layer of interpretation.

A strain recovered from stool is removed from the environment in which it was living. It is placed onto selected media under selected atmospheric conditions. Colonies are chosen, purified, expanded, identified, aliquoted, frozen, thawed, and grown again. Every step favors organisms capable of surviving that workflow.

The archived isolate is biologically real, but it is not a frozen copy of the function it performed inside the donor.

Inside the gut, bacterial behavior depends on nutrient availability, neighboring organisms, bacteriophages, oxygen gradients, bile acids, host secretions, immune pressure, spatial location, and metabolic cross-feeding. Remove the strain from that network and its gene expression and metabolic output may change dramatically, even if its genome remains largely intact.

This does not make the isolate useless. It changes what the isolate represents.

A sequence captures biological potential. A cultured strain allows that potential to be tested. Neither proves what the organism was doing in the original host.

That distinction should shape how researchers interpret the collection. An organism found in a healthy person may have contributed to health. It may also have been supported by the same diet and environment that supported health. It may be functionally redundant with several other species. It may be a marker of an ecological state rather than a driver of it.

Presence is not causation. Preservation is not validation.

The Conservancy gives science the ability to ask whether these organisms matter. It does not answer the question simply by recovering them.

A Global Collection Does Not Automatically Create Global Equity

The article is also right to treat underrepresentation as more than a technical problem. Whose samples enter microbiome science affects whose biology becomes visible, whose health becomes the standard, and who benefits from future discoveries.

But geographic inclusion is not the same thing as equitable science.

A collection can contain samples from around the world while decisions about storage, access, analysis, funding, authorship, intellectual property, and downstream development remain concentrated in a small number of institutions. It can be globally sourced and still be unevenly governed.

That does not mean the Global Microbiome Conservancy is operating inequitably. Its public materials describe participant ownership, noncommercial research access, withdrawal rights, capacity-building efforts, and international collaboration. Those commitments appear more thoughtful than the vague equity language attached to many global science projects.

Still, equity should be judged by structure, not aspiration.

The relevant questions are practical. Who decides which projects receive strains? Are scientists and communities from contributing regions represented in governance? Where are duplicate collections stored? Who controls derivative data? What happens if an academic discovery later becomes a commercial product? How are benefits shared? Can communities influence downstream uses after organisms have been cultured and distributed?

These are not accusations. They are the questions required to determine whether global sampling has produced shared scientific power or merely broader biological input.

A collection does not become equitable because it is diverse. Equity depends on who retains authority over what the collection becomes.

Biological Possibility Is Not Clinical Utility

The Conservancy may eventually contribute to important therapeutic discoveries. Its strains could reveal novel enzymes, metabolites, pathways, ecological interactions, or candidates for defined microbial communities. That possibility is one of the strongest arguments for preserving them.

Possibility, though, is not utility.

The history of microbiome science is full of organisms associated with health, disease, treatment response, inflammation, metabolism, and neurological conditions. Far fewer have survived the transition from association to mechanism, and fewer still have produced reproducible clinical benefit.

An organism can appear promising and still fail because it does not engraft, cannot compete with the resident community, requires a diet the recipient does not consume, behaves differently in another host, or produces a metabolite only in the presence of specific microbial partners. Even successful colonization does not guarantee that the organism changes a meaningful clinical outcome.

The most successful microbiome interventions have generally worked in settings where ecology was already profoundly disrupted. Fecal microbiota transplantation for recurrent Clostridioides difficile infection is effective not because clinicians identify and replace one missing ancestral organism, but because they restore colonization resistance within a damaged ecosystem.

That success has not generalized easily to obesity, inflammatory bowel disease, neurological disorders, or most other conditions associated with microbiome differences. Those diseases involve more complex host biology, more stable resident communities, and far less certainty about whether the microbiome is a cause, a consequence, or one modifier among many.

The Conservancy can provide candidate organisms. It cannot bypass the need for mechanistic studies, ecological reconstruction, host stratification, manufacturing controls, safety testing, randomized trials, and independent replication.

A freezer full of rare strains may become an extraordinary scientific resource.

It is not a pipeline of future medicines.

The Harder Question

The New York Times article moves the public discussion forward because it makes one point unmistakable. Microbiome science has studied too little of humanity and called the result universal.

The Global Microbiome Conservancy is helping correct that failure. It is expanding the known microbial world, preserving viable organisms, and creating possibilities that future scientists may use in ways we cannot yet predict.

That achievement deserves recognition.

It also deserves precision.

The Conservancy expands the map. It does not tell us what health is.

It preserves organisms. It does not preserve their original ecological meaning or establish their causal importance.

It creates a global collection. It does not prove that scientific power is globally shared.

It generates biological possibility. It does not guarantee that any preserved strain will become clinically useful.

Those are not reasons to dismiss the project. They are reasons to describe it accurately.

The collection may become one of the most valuable resources in microbiome science. Its greatest contribution may not be restoring a lost microbial past or supplying the next generation of therapeutics. It may be forcing the field to confront how little it actually knows about microbial health, function, causality, and human variation.

That is a less romantic story than rescuing the world’s disappearing microbes.

It is also the more scientifically honest one.

Source note: This essay responds to Janeen Interlandi, “"Our Bacteria Are Talking. We've Just Begun to Understand What They're Saying"published in The New York Times Magazine on July 8, 2026. The original article can be read here.

Subscribe now

A study showed that seven direct-to-consumer microbiome testing companies could analyze the same standardized stool material and return meaningfully different results.

Then nothing happened.

No public company-by-company accounting. No named responses. No visible industry reckoning. No requirement that the companies explain whether their methods failed, whether their pipelines changed, whether their reports were revised, or whether their consumer-facing claims were softened. The companies were anonymized, the study generated a brief wave of coverage, and the direct-to-consumer microbiome testing industry kept moving as if this were just another interesting little paper for the methods nerds to chew on.

The study, published in Communications Biology, evaluated seven direct-to-consumer gut microbiome testing services using standardized human fecal material developed by the National Institute of Standards and Technology. Each company used either 16S rRNA gene amplicon sequencing or whole metagenome shotgun sequencing and returned a consumer-style report. The design was simple: send standardized material through commercial workflows and see what comes back. These were not seven different people with different diets, medications, bowel habits, sampling times, and travel histories. This was standardized material moving through systems that claim to produce meaningful microbiome information.

The result was not minor technical noise. The study reported major discrepancies within and across providers, and the variability between companies was on the same scale as the biological variability between different donors. That should have set off every alarm in the building. If company-to-company variation can look as large as person-to-person variation, then what exactly is the consumer supposed to trust?

This was not just another paper showing that stool is complicated. Everyone serious already knows stool is complicated. Stool is biologically messy, spatially heterogeneous, temporally dynamic, diet-sensitive, medication-sensitive, and full of technical traps. That is precisely why this field needs more discipline, not less. Complexity should increase the burden of transparency. It should not become a hiding place.

But that is what we have allowed to happen.

When microbiome results disagree, the standard explanation is usually technically correct. Different collection kits, stabilization chemistries, DNA extraction protocols, sequencing methods, read depths, classifiers, reference databases, pipelines, thresholds, and comparator populations can all change the result. Fine. All true. Also very convenient. At some point, “our methods are different” stops being an explanation and starts becoming a shield.

The field lets people hide behind that shield too easily.

A company can sell a microbiome score with confidence on Monday, then retreat into methodological complexity on Tuesday when someone asks why the same sample tells a different story somewhere else. A company can imply personalization when selling the test, then plead uncertainty when the measurement is challenged. A company can wrap itself in sequencing, algorithms, and “gut health insights,” then act like it is merely offering harmless curiosity when asked whether the result is reproducible.

No. Pick a lane.

If this is entertainment, call it entertainment. If it is exploratory wellness information, say that clearly and stop dressing it up like medical insight. If it is clinically meaningful, prove it. But do not sell people a health-flavored report built on methods you will not fully explain, uncertainty you will not clearly communicate, and recommendations you cannot adequately validate.

That is the core problem. These companies are not just selling raw sequence data. Most consumers are not buying FASTQ files and spending their weekend comparing taxonomy tables, because most consumers have lives and better hobbies. They are buying interpretation. They are buying the claim that this stool sample says something meaningful about their body and might guide a decision.

Eat this. Avoid that. Take this. Improve this score. Support this bacterium. Reduce that risk. Optimize your gut.

Once a company turns a measurement into a health-flavored recommendation, it enters a higher-responsibility zone. It does not get to sell certainty at the front door and hide behind uncertainty at the back door. A colorful dashboard is not accountability. A proprietary algorithm is not accountability. A footnote about “advanced sequencing” is not accountability. A wellness report with decimals and lifestyle tips is not accountability. It is a lab coat draped over a marketing funnel.

The NIST-associated study should have forced every serious company in this space to answer basic questions.

Was your company one of the seven?

Did you identify your own performance?

Did your replicates agree? Did your workflow detect organisms other systems missed, or miss organisms other systems detected?

Did your quality-control process catch unexpected variation?

Did you update your extraction protocol, sequencing approach, database, classifier, pipeline, or report language?

Did you add uncertainty estimates to consumer-facing results?

Did you reduce or remove recommendations that your analytical performance cannot support?

Those questions should not be treated as aggressive. They are the minimum cost of selling microbiome meaning to the public. Serious testing systems compare themselves against standards, participate in proficiency testing, document methods, report uncertainty, explain failures, and update protocols. They do not just shrug and say biology is hard. Biology is hard. So is building airplanes. We still expect the bolts to be inspected.

This is where I think the microbiome field needs to take a harder look at itself. We have become too comfortable letting complexity excuse weak accountability. We tolerate vague methods because the systems are complicated. We tolerate proprietary analysis because companies say the pipeline is their secret sauce. We tolerate soft claims because they are not quite medical claims. We tolerate inconsistent outputs because stool is messy. We tolerate consumer confusion because the field is “still evolving.”

The microbiome field cannot keep asking for credibility while letting commercial testing companies operate like black boxes. If a result is sensitive to extraction method, sequencing platform, database version, read trimming, filtering, and classification pipeline, then those are not boring technical details. They are the machinery of the result. They should be disclosed, versioned, auditable, and reported in language that clinicians, researchers, regulators, and educated consumers can understand.

The field already has pieces of a better path. NIST exists to advance measurement science and standards, and this study used NIST-developed human fecal material precisely because standardized materials are needed to evaluate analytical performance. NIST has also released reference material to help gut microbiome researchers compare methods. The problem is not that standards are impossible. The problem is that standards are inconvenient.

Standards reduce ambiguity. They expose weak methods. They make marketing claims easier to challenge. They make it harder to hide behind proprietary fog. That is exactly why they are needed.

A serious microbiome testing ecosystem would have standardized reference materials, inter-laboratory comparisons, clear reporting expectations, versioned pipelines, public-facing uncertainty language, and a clean separation between exploratory wellness information and clinically actionable results. It would require companies to show whether a “score” is analytically reproducible, biologically meaningful, and clinically useful.

Those are three different things. Analytically reproducible means the same sample gives a similar result when tested again. Biologically meaningful means the result reflects something real about the microbial community. Clinically useful means acting on the result improves a decision or outcome. The direct-to-consumer microbiome industry often talks as if all three have been solved. They have not.

Different methods can be valid. Different methods can answer different questions. Different methods can have different strengths. But “different” is not automatically “better.” A company claiming superiority should show superiority. A company claiming clinical relevance should show clinical relevance. A company claiming personalized recommendations should show that its measurement can support personalization. Otherwise, we are not looking at precision health. We are looking at precision theater.

The accountability problem does not stop with the companies. It also includes how the study was presented. The paper says seven providers were selected after a web search, ordered through standard consumer channels, and not told about the study until after the reports were received. That blinding makes sense for the experimental design because the companies needed to behave as they would for ordinary consumers. But after the results were in, the public still did not get the company names. The providers became letters, and the industry became a faceless blur.

That decision may have been defensible from a research, institutional, or legal perspective. The authors may have wanted to avoid lawsuits, prevent the paper from becoming a consumer ranking exercise, protect the focus on measurement science, or preserve the possibility of future collaboration with companies. NIST’s public write-up says the team contacted the companies after the study and that most were happy to work with them on future research. That sounds constructive. But collaboration is not the same thing as public accountability.

Anonymity has consequences. When companies are hidden behind provider labels, consumers cannot know who failed, who performed better, who produced inconsistent replicates, who flagged questionable organisms, who delivered contradictory interpretations, or who generated reports that should have triggered internal quality-control alarms. Clinicians cannot tell patients which companies showed better analytical performance. Researchers cannot openly compare claims against named workflows. The worst performers get shelter inside the group average, and the better performers do not get credit for doing the work better.

The companies were allowed to become letters instead of actors. Their reports became data points instead of consumer products that real people might trust. Their failures, if they were failures, became anonymous variation. That may be useful for a measurement-science paper, but it is weak medicine for consumers. If people are being told not to trust the market, they deserve to know which parts of the market failed the test.

This is especially important because the study itself was not written from outside the microbiome world. The competing-interest statement disclosed that Jacques Ravel is a co-founder of LUCA Biologics, a microbiome-focused biotechnology company developing live biotherapeutics. That does not mean Ravel had a direct conflict with the seven gut microbiome testing companies, and I found no public evidence that he, Stephanie Servetas, Scott Jackson, Diane Hoffmann, or Kristine Gierz had disclosed financial ties to the specific anonymous gut-testing services evaluated in the paper. But the disclosure still matters. When a study evaluates commercial companies, anonymizes them, and includes an author with disclosed microbiome-industry relationships, readers deserve a fuller explanation of the accountability tradeoff.

This is not an accusation that the authors protected specific companies. That would overstate the evidence. The critique is narrower and stronger. Why were the companies not named after the blinded phase was complete? Were legal concerns involved? Were institutional concerns involved? Were the authors prioritizing future collaboration over consumer-facing transparency? Were the companies given a chance to publish responses? Were any technical corrective actions documented? These are fair questions because the study sits at the intersection of measurement science, consumer protection, industry behavior, and public trust.

The authors deserve praise for doing the study. It was needed, and the design exposed a serious problem. But they also deserve pressure because a failed stress test without names creates a strange kind of warning. Consumers are told to be cautious, but not told cautious of whom. Companies are told the industry has a reproducibility problem, but not asked to answer publicly for their own performance. Everyone gets to agree that standards are needed while nobody has to stand next to their own report and explain what happened.

The press coverage around the study largely reinforced the same message. At-home gut microbiome tests can produce inconsistent results, and consumers should be cautious. That message is correct, but caution is not enough. “Buyer beware” might work for gas station sunglasses. It should not be the final accountability framework for a testing industry that wraps itself in sequencing, algorithms, health optimization, and personalized recommendations.

If a company wants to sell curiosity, it should label the product as curiosity. If it wants to sell research-grade information, it should say so clearly. If it wants to imply clinical meaning, it should prove analytical reliability, biological relevance, and clinical utility. Once a company sells health meaning, it inherits responsibility.

The NIST-associated study did not prove that all microbiome testing is useless. That would be too simple, and simple is usually where bad arguments go to feel pretty. The study showed something more important: the direct-to-consumer microbiome testing ecosystem is not yet behaving like a mature measurement field.

The next version of this work should not stop at seven anonymous letters. It should name the companies, publish the consumer-facing reports with appropriate legal and ethical review, include company responses, compare performance against standardized material, and ask whether each provider’s claims are supported by its own analytical reproducibility. If company names cannot be published, that limitation should be treated as central, not incidental, because anonymity protects the very market the study is asking consumers to distrust.

The same standardized stool material should not produce conflicting consumer microbiome stories and then vanish into the literature like nothing happened. If the companies were told their results differed, they should have had to explain what they found, what they changed, and what claims they could still honestly defend.

The field does not need another polite conversation about complexity. It needs consequences. It needs named accountability. It needs standards with teeth.

Without that, this is not a mature testing industry. It is a collection of black boxes selling confidence they have not earned.

The wellness industry has turned a stool sample into a personality test with a checkout page.

You mail in a small plastic tube of shit. A company runs sequencing. A dashboard appears.

Then comes the verdict:

Your gut health score: 62.
Your diversity: below optimal.
Your microbiome age: older than your actual age.
Your inflammation risk: elevated.
Here are 12 foods to eat, 6 foods to avoid, and 3 supplements we would be delighted to sell you.

It looks clinical. It feels personalized. It has charts.

That does not make it medicine.

The direct to consumer microbiome testing industry has convinced people that a single stool sample can reveal whether their internal ecosystem is thriving, failing, aging prematurely, metabolically broken, inflamed, anxious, or one artisanal probiotic away from transcendence.

Much of that confidence is wildly ahead of the evidence.

The problem is not that microbiome science is fake. It is one of the most important areas of biomedical research happening right now.

The problem is that companies have taken an extraordinarily complicated research field and compressed it into a consumer product that often delivers much more certainty than the underlying science can support.

A microbiome score is not a diagnosis. It is not a prognosis. It is not a medical grade measure of whether you are healthy.

It is an interpretation generated by one company, using one sampling method, one sequencing workflow, one reference database, one statistical model, and one set of assumptions about what your gut is supposed to look like.

That is a lot of machinery hiding behind a number with a little green circle around it.

Different Companies Can Give You Different Guts

This should make people furious.

In a 2026 study, researchers sent the same standardized human stool material to seven direct to consumer microbiome testing services.

The companies did not simply produce slightly different interpretations.

They produced major discrepancies in the microbes they detected and in the conclusions they drew from the same material. The variation between providers was on the same scale as the biological variation usually seen between different human donors.

Put differently: the lab you choose could matter as much as the person whose gut was supposedly being measured.

One company may tell you to eat more fermented foods. Another may tell you to cut particular fibers. A third may recommend supplements. A fourth may flag a suboptimal score and steer you toward a subscription.

Same shit. Different prophecy.

This is not a minor technical footnote. It is the central problem.

Before a test can be useful, it has to demonstrate three things.

Analytical validity: Can the company accurately and reproducibly measure what it says it measures?

Clinical validity: Does that measurement reliably relate to a specific health condition or meaningful outcome?

Clinical utility: Does acting on the result improve anything that matters?

Too many microbiome companies leap from “we detected bacteria” to “we can tell you what to eat.”

Those are not the same sentence.

There Is No Universal “Healthy Microbiome”

This should end about half the marketing copy in the industry.

There is no single healthy microbiome.

There are microbial patterns associated with health. There are microbial functions relevant to metabolism, immune regulation, colonization resistance, drug metabolism, and inflammatory disease. There are signatures associated with particular conditions.

But “healthy” is not one fixed list of bacteria.

A healthy microbiome for a 25 year old endurance athlete in rural Kenya does not look identical to one for a 55 year old office worker in Portland, Oregon. Diet, medications, geography, age, sleep, infections, pregnancy, stress, exercise, socioeconomic conditions, sanitation, travel, alcohol, fiber intake, antibiotics, and plain old biology all shape the microbial community.

Your microbiome is also dynamic. Diet, illness, medications, travel, bowel habits, and sampling conditions can all shift what one stool sample captures.

That means a company may compare your stool sample with a reference population that does not resemble you in any meaningful way, then present the result as though it has discovered something intrinsic and stable about your body.

That is not precision medicine.

That is a statistical horoscope with more Latin names.

An international expert consensus statement on microbiome testing concluded that evidence supporting routine clinical usefulness remains scarce. It also warned that direct to consumer tests have proliferated without proven value in clinical practice.

A Score Creates Authority Without Accountability

The score is the trick.

Humans love scores because they feel objective. A score turns uncertainty into a target. It gives people something to optimize, compare, improve, obsess over, and post about.

Nobody wants to hear that their gut is a dynamic ecosystem shaped by hundreds of variables, most of which cannot be captured by one stool sample and a proprietary algorithm.

They want to know whether they got an 82.

But what does an 82 mean?

If your microbiome score improves from 62 to 74, have you reduced disease risk? Improved immune function? Changed inflammation? Increased resilience? Improved bowel habits? Lowered cardiometabolic risk?

Maybe. Maybe not.

Unless the company can show that its score predicts a specific outcome and that changing the score improves that outcome, it is mostly a branded metric.

The number may be sophisticated. The algorithm may use real research. The sequencing may be technically impressive.

That still does not make the output clinically meaningful.

A beautifully designed dashboard can be scientifically underpowered. Silicon Valley has been proving that for years.

“Personalized” Does Not Automatically Mean Better

Personalization is one of the most abused words in wellness.

It sounds like the opposite of generic advice. It sounds medically advanced. It sounds like your body is finally being understood as the unique and complicated organism it is.

Sometimes personalization is useful.

A dietitian adapting nutrition guidance to someone’s medical history, medications, symptoms, lab values, food access, culture, preferences, gastrointestinal tolerance, and goals is personalization.

A gastroenterologist using validated testing to investigate symptoms is personalization.

A microbiome researcher studying carefully defined cohorts to identify reproducible disease signatures is personalization in development.

Sending a stool sample to a company that tells you your gut age is 47 when you are 38, then recommends a powder, is consumer theater wearing a lab coat.

The recommendation may even be reasonable. Eat more plants. Increase fiber gradually. Exercise. Sleep. Reduce ultra processed food. Do not take antibiotics casually.

Fine. Good advice.

But it does not become more scientifically profound because it arrived after a sequencing run and a $249 invoice.

What a Responsible Company Should Be Able to Show You

A serious microbiome testing company should tell you:

• What it actually measured

• How stable and reproducible the result is

• Which reference population it used

• How its score was developed and validated

• What health outcome that score predicts

• How much uncertainty surrounds the result

• Whether following its recommendations improves a meaningful outcome

That is the minimum.

If the answer is buried in proprietary language, hidden behind a dashboard, or replaced with a cartoon of smiling bacteria, you are not looking at precision medicine.

You are looking at branding.

The Industry Needs to Stop Pretending It Has Finished the Assignment

Microbiome diagnostics may eventually have important clinical roles in tightly defined settings.

The likely future is not a universal gut health score. It is carefully validated testing for specific clinical questions, in specific populations, using methods that produce reproducible results.

That could include tools to identify disease subtypes, predict drug response, stratify patients, detect infection risk, or monitor therapeutic response.

But the gap between promising research and responsible consumer products remains enormous.

The current direct to consumer model often asks customers to pay for biological ambiguity, then converts that ambiguity into confident language.

That is backwards.

The industry should do the hard work first:

• Standardize collection and processing methods.

• Publish reproducibility data.

• Validate claims in diverse populations.

• Show that results predict meaningful clinical outcomes.

• Demonstrate that recommended interventions improve those outcomes.

• Be explicit about uncertainty.

• Stop calling every deviation from a company’s reference database “dysbiosis.”

• Stop telling people their microbiome is “imbalanced” when nobody can define what their balance was supposed to be.

• Stop handing consumers a score that looks like a blood pressure reading when it is closer to a proprietary weather forecast.

What Consumers Should Ask Before Buying a Test

Before you spend money on a microbiome test, ask five questions.

What exactly is this test measuring?
Bacterial DNA? Species abundance? Functional genes? Metabolites? A score built from a proprietary model?

Can the company show reproducibility?
Would the same sample produce the same result if tested again? Would another validated laboratory reach a similar conclusion?

What health outcome does this predict?
Not “gut wellness.” Not “balance.” Not “resilience.” What actual outcome?

Has the company shown that acting on the result improves anything?
A recommendation is not evidence simply because it is personalized.

Would I make a different decision if I never took this test?
If the answer is “eat more plants, sleep more, move more, and stop buying random supplements,” you may not need a stool subscription to get there.

The Bottom Line

The microbiome deserves better than this.

It deserves better science, better standards, better regulation, better communication, and much less bullshit.

People are not stupid for wanting answers. They are trying to understand chronic symptoms, metabolic issues, digestive problems, mood changes, fatigue, inflammation, and the feeling that modern medicine has left them with too few useful options.

That vulnerability is exactly why this industry has to be held to a higher standard.

A microbiome test can be interesting.

It can be educational.

It can be a useful research tool.

But until a company can prove that its results are reliable, clinically meaningful, and actionably better than ordinary evidence based guidance, its microbiome score is not a health score.

It is a product feature.

And consumers deserve to know the difference.

For more science and tools to help you make better gut and microbiome decisions check out guttitude. You can evaluate your probiotics, check known associations between the microbiome and variouys diseases and determine whether a company’s claims are legit or mostly hype,

References

Servetas SL, Gierz KS, Hoffmann D, et al. Evaluating the analytical performance of direct to consumer gut microbiome testing services. Communications Biology. 2026;9:269. doi:10.1038/s42003-025-09301-3

Porcari S, et al. International consensus statement on microbiome testing in clinical practice. The Lancet Gastroenterology & Hepatology. 2025;10:154-167.

Supports gut health.
Balances the microbiome.
Helps digestion.
Boosts immunity.
Restores your flora.

Most of those claims are too vague to mean much.

“Probiotic” is not a diagnosis, a treatment category, or a guarantee of benefit. …

Read more